Vascular changes are consistent early findings in patients with SSc and often precede the development of fibrosis. Despite a significant reduction in the capillary density, there is paradoxically no sufficient angiogenesis in the skin of SSc patients. By using a pO 2 histograph, we showed that low pO 2 values are overt in involved skin of patients with SSc. In vitro, real-time PCR revealed a 3.7-fold upregulation of the potent angiogenic growth factor VEGF in SSc fibroblasts after hypoxic exposure compared to normoxic controls. In situ hybridization for VEGF in skin biopsies of patients with SSc showed an overexpression of VEGF mRNA by fibroblasts and mononuclear infiltrates, whereas its expression was limited to keratinocytes in healthy control biopsies. In contrast to the SSc skin, HIF-1 alpha protein was found to be coexpressed with VEGF in healthy skin samples, indicating that the constitutive VEGF synthesis in the skin is driven by this transcription factor. Additionally, we showed that the lack of angiogenesis in SSc is not due to a reduced bioavailability of the overexpressed VEGF, since the VEGF receptors Flk-1 and Flt-1 were found to be expressed on endothelial cells of patients with SSc, but not in healthy controls, and since SSc patients had severely elevated serum levels of VEGF compared to healthy controls. Despite the enhanced levels of VEGF, serum samples of SSc patients did not induce angiogenesis in the vivo chorion allantois membrane assay, indicating that the proangiogenic effects of VEGF may be outweighed by angiostatic factors. The hypothesis that VEGF synthesis has to be above an individual threshold in SSc patients to induce angiogenesis was further strengthened by the finding that patients without fingertip ulcers had significantly higher levels than patients with fingertip ulcers. Interestingly, the angiostatic factor endostatin was elevated in a subset of patients and thus may counteract directly the biologic effects of VEGF in SSc patients. Serum levels of VEGF were also correlated significantly with disease severity parameters including antitopoisomerase antibodies. These results suggest that therapeutic application of VEGF by either gene transfer or as a recombinant protein might be a novel option in SSc.
Increasing attention has recently been paid to the normal intestinal flora as a potential source of etiological agents in RA. Changes in the intestinal flora, due to fasting or diet, have been shown to reflect improvement of the patients when they are divided into highand low-responders. Previously, evidence has also been presented that intestinal flora in the early RA is different from that of non-RA controls, due primarily to anaerobic bacteria. The present study was designed to compare the fecal microbiota of the patients with early RA with the microbiota of the control patients using 16S rRNA oligonucleotide probes, detecting a variety of anaerobic bacteria in the normal intestinal flora. Fecal samples of 25 early, disease modifying antirheumatic drugs, naive RA patients and 23 control patients suffering from noninflammatory pain were investigated. The contribution of five bacterial groups was determined by using whole cell hybridization with seven fluorescently labeled 16S rRNA-targeted oligonucleotide probes. These probes cover one third to a half of the total bacteria in the human intestine. Patients with early RA had significantly less bacteria belonging to the Bacteroides, Prevotella and Porphyromonas genera than the controls (4.7% vs. 9.5%, P = 0.00005). The finding was confirmed with a probe specific for bacteria of the Bacteroides fragilis group (1.6% vs. 2.6%, P = 0.02). The samples of RA patients and the controls did not differ significantly when five other oligonucleotide probes were applied. They were detecting bacteria in the genera Atobium, Coriobacterium, Collinsella, Bifidobacterium and Fusobacterium, and in the Eubacterium rectaleClostridium coccoides group. We conclude that the content of anaerobic bacteria in the intestinal flora of the patients with early RA is significantly different than that of the controls. The number of bacteria belonging to the Bacteroides-Prevotella-Porphyromonas group was, on average, in RA patients only half that of the controls. If this finding can be confirmed, together with a recent suggestion that certain Bacteroides species are required for fortification of the barrier function in the intestinal epithelium, it adds further evidence to the hypothesis that intestinal bacterial flora plays a role in the etiopathogenesis of RA. Mice heterozygous for the Del1 transgene locus with short deletion mutation in type II collagen gene develop degenerative changes in the knee joints from the age of 3 months which progresses to an end-stage OA by the age of 12-15 months. This study focuses on expression and distribution in syndecan-1 during development of osteoarthritic cartilage degeneration. Human samples from cartilage of osteoarthritic patients was studied for comparison. Northern analysis of total RNA extracted from knee joints of transgenic Del1 mice and their nontransgenic controls was used to monitor changes in syndecan-1 levels during development, growth, aging and cartilage degeneration. Immunohistochemistry was used to study the distribution of syndecan-1 in mouse and human samples. Syndecan-1 was present in the knee joints during development, growth and aging both in the control and Del1 mice, the mRNA levels being highest in the aged and late osteoarthritic samples.
The most intensive immunostaining of syndecan-1 was seen in synovial tissue and adjacent of the defected areas of cartilage and menisci. In addition, some individual cells or cell clusters in the superficial zone of articular cartilage contained syndecan-1. In human osteoarthritic cartilage, dedifferentiated syndecan-1 positive cells were seen in corresponding locations to those in Del1 mice. We demonstrated syndecan-1 for the first time in aging and degenerating murine articular cartilage and synovial tissue. Syndecan-1 is involved in phenotypic modulation of the articular chondrocytes and during osteophyte formation. In this Del1 mouse model, proliferation plays a role forming characteristic chondrocyte clusters near the surface, while apoptosis occurs primarily in the calcified cartilage. These results suggest that syndecan-1 has a role in the functional activity of the chondrocytes during the disease process. Control of syndecan expression in articular cartilage could be an attractive target for therapeutic interventions in the future.
Recent studies suggest that osteoclasts may contribute to bone erosions in the joints of animal models of arthritis and human rheumatoid arthritis. We therefore adressed the question, can bone destruction occur in an osteoclast free model of arthritis? To answer this question, c-Fos knockout mice (c-fos-/-) were crossed with mice overexpressing human soluble TNF (huTNFtg). C-fos-/-mice lack osteoclasts and are therefore osteopetrotic since c-fos is essential for the signaling of osteoclast differentiation. HuTNFtg mice develop a severe and destructive arthritis through the signaling of huTNF via the p55 TNF receptor. The resulting four groups of mice (wildtype, huTNFtg, c-fos-/-and c-fos-/-/huTNFtg) were followed over 10 weeks and assessed for joint inflammation and joint destruction. Clinical features of arthritis, such as paw swelling and reduction in grip strength progressed equally in both huTNFtg and c-fos-/-/huTNFtg mice. Clinical features of arthritis were absent in c-fos-/-and wildtype mice. Quantitative histological evaluation of joint sections revealed no difference between huTNFtg and c-fos-/-/huTNFtg mice in the size of inflammatory synovial lesions. As previously described, huTNFtg mice showed severe bone erosions in all joint compartments. Bone resorption was characterized by the abundant presence of osteoclasts, as confirmed by cells positive staining for TRAP and the calcitonin receptor. Furthermore, the number of osteoclasts and the size of bone erosions were significant. In contrast, c-fos-/-/huTNFtg mice did not show any form of bone destruction despite the presence of severe inflammatory changes. C-fos-/-/huTNFtg mice were confirmed to lack osteoclasts by negative TRAP staining and the presence of osteopetrosis. Controls (c-fos-/-mice and wildtype mice) did not show histological signs of inflammation or bone erosion. In conclusion, these data clearly show that TNF-mediated bone erosion is triggered by osteoclasts, and the absence of osteoclasts turns TNF-mediated arthritis from destructive to non-destructive arthritis.
Interaction of intimal fibroblasts with intracavitary fibrin: a morphologic follow up in ovalbumin arthritis
O Sánchez-Pernaute, R Largo, I Díez-Ortego, MA Alvarez-Soria, E Calvo, M Lopez-Armada, G Herrero-Beaumont
Jiménez Díaz Foundation, Madrid, Spain
Background: An imbalance between haemostasia and fibrinolysis, and subsequent fibrin generation within the rheumatoid joint could have a role in disease perpetuation. Objective: To study fibrin formation at the synovial space in a model of rheumatoid arthritis, and its possible role in activating the synovial cells from inside of the cavity. Methods: Antigen arthritis was induced by injecting ovalbumin into rabbits' knees. We looked for the appearance of fibrin in the effusion and at the inflamed tisues with immunohistochemistry, in a sequential fashion (from 24 hour to 1 week after disease induction). Morphologic changes at the intimal synovial surface in contact with fibrin matrices were studied over a long period of time by several qualitative variables. Analysis of the variables was carried out with Kruskall Wallis and Mann Whitney nonparametric tests, and linear regression was performed using the least squares method.
Results: Fibrin aggregates appeared from the initial stages of the disease at the synovial effusion. Later on, they were localised on the synovial surface. Differentiation of the aggregates from the underlying synovial tissue was easy at the beginning, but then progressive changes were noted at the fibrin-tissue interface, ending with the invasion of the aggregates by synovial cells and their incorporation into the tissue. The process involved cross-linking of fibrin matrices with fibronectin, and synoviocyte proliferation and migration. Conclusion: Fibrin aggregates generated inside the joint cavity may constitute a source of activation and acquisition of invasiveness of synovial fibroblasts, a process to explore between the perpetuating mechanisms of rheumatoid arthritis.
Vascular endothelial growth factor (VEGF) expression in muscle tissue and the effect of corticosteroid therapy in patients with poly-and dermatomyositis

IE Lundberg
Karolinska Institutet, Stockholm, Sweden
Background: Previous studies on pathogenic mechanisms indicate that the microvessels have a role in the disease mechanisms in polymyositis (PM) and dermatomyositis (DM) . A reduced number of capillaries has been reported and this observation together with the increased expression of interleukin-1 and TGF-β suggest that there might be an hypoxic condition in the inflamed muscle tissue that could explain some of the clinical symptoms.
Aim of study:
To further test this hypothesis we investigated if vascular endothelial growth factor (VEGF), which is upregulated by hypoxia, is expressed in muscle tissue in patients with PM and DM. A second aim was to investigate whether VEGF expression is affected by corticosteroid therapy.
Patients and methods:
Six patients with PM and 4 with DM were investigated. A first muscle biopsy was taken at diagnosis and a second after 3-6 months with corticosteroid therapy. VEGF expression was investigated by immunohistochemistry using a rabbit polyclonal IgG antibody. Both conventional microscopic evaluation and computerised image analysis were used for evaluation of VEGF expression. Results: These are our preliminary data: First biopsy: with conventional microscopic evaluation VEGF expression was observed in the endothelial cells of the microvessels in 9/10 patients and in larger vessels such as arterioles and venules in all patients. VEGF was also expressed in muscle fibres in all, and in mononuclear inflammatory cells in 3/10 patients. In the second biopsy, VEGF expression was still present in endothelial cells of capillaries and larger vessels as well as in muscle fibres, but with a seemingly weaker expression in the endothelial cells of PM patients and an increased expression in the DM patients. With computerised image analysis the results were similar. Conclusion: VEGF is expressed in endothelial cells of capillaries and slightly larger vessels, in muscle fibres, and in occasional inflammatory cells in muscle tissue from patients with poly-and dermatomyositis. After corticosteroid therapy the expression decreased in some patients and increased in other patients. Whether or not the changed VEGF expression has any clinical significance and correlates with changes in muscle function still needs to be analysed.
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Etiology of a spontaneous autoimmune joint disease in mice J J Sinkora
Institute of Microbiology, Novy Hradek, Czech Republic
Aims: To reveal which microbes are capable of inducing Ankylosing Enthesopathy (ANKENT), a spontaneous joint disease in susceptible mouse strains. Besides gender and age (young males afflicted) and genes (B57B6 background with some H-2 haplotypes being more effective), environmental factors (stress and microflora) have also been suggested to play a role in ANKENT onset. We have recently shown that ANKENT does not develop under germfree (GF) conditions. Materials and methods: To identify ANKENT-triggering bacteria we transferred B10.BR ANKENT-prone mice into germfree conditions. Individual colonies were then associated with selected microbial cocktails. The incidence of ANKENT and immune system development has been studied in these gnotobiotic colonies.
Results: When compared to GF and conventional (CV) males (prevalence of 0 and ~20%, respectively), high incidence (~20%) of ANKENT has been revealed in mice associated with a cocktail of bacteria isolated from the intestine of an ANKENT-afflicted CV male. In the cocktail, no strong pathogens and Enterobacteriae like E. coli or Salmonella were present. The first ANKENT case has also been observed in mice colonized with a more restricted cocktail containing two selected gram-positive microbial strains. Surface phenotype of lymphocytes isolated from systemic lymphatic tissues, MALT and diseased joint were characterized. No significant differences in lymphatic tissues were detected between individual experimental groups. However, the prevalence of CD4 + cells among joint-infiltrating lymphocytes was recorded. Discussion: The presence of viruses, eukaryotic micro-organisms and noncultivable bacterial species (like segmented filamentous bacteria) is not required for ANKENT incidence. Although the autoimmune nature of the disease has not definitely been proven yet, the existence of specific ANKENT-triggering microbes strongly supports this hypothesis. The ANKENT-triggering agents are currently characterized by rRNA analysis.
Investigation of serum cartilage oligomer protein (COMP) levels in rheumatoid arthritis (RA)
M Brozik, L Hodinka, E Palkonyai, I Sznts, M Seszták, Zs Schmidt, U Böhm, K Merétey
National Institute of Rheumatology, Budapest, Hungary
RA is a disease characterised by an inflammatory process in the synovium and a degradation process of the joint cartilage. When articular cartilage matrix is degraded by a disease process, protein fragments are produced and some of them subsequently appear in the blood circulation and can be used to monitor cartilage degradation. COMP was first described by D. Heinegard as a noncollagenous protein primarily found in articular cartilage. COMP levels of serum and synovial fluids have been shown to have potential as prognostic markers of osteoarthritis and RA progression as well. For the detection of COMP mainly monoclonal antibody based competition ELISA systems have been described. Recently on the basis of the research group of D.Heinegard a two-site sandwich ELISA test from AnaMar Medical AB has been available in wich two monoclonal antibodies directed against separate antigenic determinant of COMP molecule are applied.
Using the COMP ELISA test of 'AnaMar' we measured the serum COMP levels of 47 patients who fulfilled the ACR criteria of RA. Duration of the disease varied between 3-6 years. CRP and RF levels were also measured from the same sample. Patients were grouped by clinical activity, radiological progression and also by RF and CRP positivity. Our results showed that there was no difference between the serum COMP levels of seropositive and seronegative patients (11.4 vs. 10.71 ng/ml). Serum COMP levels of clinically active patients (11.7 ng/ml) were higher than of patients with inactive disease (10.5 ng/ml) (P<0.08). The average COMP levels of the radiologically progressive group was higher (12.5 ng/ml) than that of the nonprogressive ones (10.3) (P<0.06). Statistically the highest difference was found between patients with elevated CRP (12.3 ng/ml) and those with normal CRP levels (8.8 ng/ml) (P < 0.03). Significant correlation was also found between serum CRP and COMP levels R:0.54 (P < 0.003). These results confirm previous findings that the serum COMP level reflects the actual degree of cartilage destruction ongoing during the inflammatory process of arthritis, thus can be a useful marker in predicting radiological progression and in monitoring the effectiveness of the treatment of RA. Methods: Monocytes were isolated from blood of 10 RA-patients and 10 healthy controls and cultured for 7 days with M-CSF to obtain macrophages. Using FACS analysis, the expression of FcγRI, II and III was determined. At day 7 cells were stimulated with heat aggregated gamma globulins (HAGG) and 24 hours thereafter cytokine production was measured. In addition, immunohistochemistry was performed on synovial biopsies of knee joints of 27 RA patients and 5 controls. FcγRI, II and III were detected, as well as several inflammatory mediators. Results: Macrophages derived from PBMC of RA patients showed a significantly higher expression of FcγRII (45%) and FcγRIII (15%) compared to controls. When RA cells were stimulated with HAGG, we found higher TNFα production. Also, when matrix degrading gelatinase/collagenase was detected, a significantly higher activity of these enzymes was found in the supernatants of HAGG stimulated RA macrophages vs. controls. Underlining these findings, we found highly significant positive correlations between the expression of FcγRII and III and the degree of inflammation in the joint in RA patients, but not for FcγRI. FcγRII and III expression was higher (respectively 80% and 125%) in RA synovium compared to controls. TNFα expression in the synovium was correlated with FcγRIII expression (r=0.51). MMP-1 expression was strongly correlated with FcγRI, II and III (respectively r=0.48, 0.60 and 0.62) . FcγR expressions also correlated well with other cytokines, for example, IL-18 (positively: r=0.63) and IL-12 (negatively: r=-0.46).
Conclusion:
Macrophages of RA patients express higher levels of FcγRII and III, resulting in elevated production of TNFα, and MMP-1. In addition, differences in FcγR expression in the synovium may also lead to different cytokine patterns. These data suggest that disturbed FcγR expression plays a role in RA pathology.
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IL-18 expression in synovial biopsies of patients with active rheumatoid arthritis is associated with enhanced levels of both IL-1 and TNFα α LAB Joosten, P Barrera, E Lubberts, AB Blom, B OppersWalgreen, LAM van den Bersselaa, WB van den Berg
UMC Nijmegen, Nijmegen, The Netherlands
Objective: The present study was performed to examine the expression patterns of IL-18 in synovial biopsies of patients with active RA. In addition, we determined whether expression of this primary cytokine was related to expression of TNFα, IL-1β, IL-12, IL-17, and adhesion molecules or cell markers. Synovial knee biopsies were taken from 29 patients with  active RA and were immunohistochemically stained for TNFα,  IL-1β, IL-12, IL-17, and IL-18. Furthermore, ICAM-1, VCAM-1,  E-selectin, CD3, CD14 , and CD68 were stained. Both paraffin and cryo-sections were used for the detection of cytokines, adhesion molecules or cell markers. Five biopsies per patient were analyzed. Results: IL-18 staining was detectable in 80% of the RA patients both in lining and sublining. TNFα was present in 50% of the RApatients, whereas IL-1β was seen in 90% of the patients. When staining for TNFα was positive, variable location of TNFα was seen in the synovial lining, sublining layer and endothelial cells. IL-1β staining was consistent in all three compartments. IL-12 was predominantly expressed in the sublining in 59% of the RA patients, whereas only 24% of the patients stained positive for IL-12 in the lining. Of interest, IL-17 staining was obvious in 70% of the RA patients, and only seen in the sublining layer. ICAM-1 and E-selectin staining was only seen in the endothelial cells, whereas VCAM-1 was noted in the synovial lining and endothelial cells. IL-18 expression in the synovial lining was positively correlated with both IL-1 (r=0.71, P < 0.0001) and TNFα (r=0.68, P < 0.0008). In addition, IL-18 expression correlated with both microscopic inflammation scores (r=0.78, P < 0.0001) and macrophage marker CD68 (r=0.64, P < 0.0007) expression. Furthermore, IL-18 was positively correlated with both acute phase markers ESR (r=0.61, P < 0.0004) and CRP (r=0.57, P > 0.001).
Methods:
Conclusion:
Our results showed that IL-18 expression is associated with elevated levels of TNFα, IL-1β in synovial biopsies of patients with active RA. In addition, synovial IL-18 expression correlates with both acute phase markers ESR and CRP. These data indicated that IL-18 is a primary proinflammatory cytokine in RA that drives local IL-1/TNFα production and may be involved in enhanced acute phase protein levels.
Gene regulation and genetics
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A gene in the telomeric HLA complex distinct from HLA-A is involved in predisposition to juvenile idiopathic arthritis (JIA)
We have been studying the intracellular signaling pathways in chronically activated T cells involved in effector responses and promoting the inflammatory process, and have been struck by the extent to which T cells stimulated with TNF for prolonged periods in vitro resemble RA synovial T cells. For example, TNF upregulates expression of the activation antigen CD69, induces non-deletional and reversible hyporesponsiveness to TCR ligation by uncoupling proximal TCR signalling pathways, and represses CD28 gene expression. We have explored the possibility that systematic expression profiling of murine T cell hybridomas stimulated with pM concentrations of TNF under controlled conditions might provide further insight into the phenotype and function of cytokine activated T cells, as well as the mechanisms through which TNF uncouples TCR signal transduction pathways. Expression profiling has been performed using medium density spotted arrays based on the Compugen™ gene set. This comprises 9,215 oligonucleotide 50-mer elements including housekeeping genes and "landing lights", and covers 7,524 known mouse genes (representing 17K RNAs and 303K ESTs). Genes whose expression are altered by TNF treatment have been identified by measuring the fluorescence ratio of Cy5-and Cy3-labeled target cDNA bound to each probe following hybridization of differentially labeled cDNA pools, prepared from TNF stimulated (Cy5) or control (Cy3) T cells. Based on this simplistic analysis, clusters of genes that appear to be differentially regulated in chronic TNF treated T cells have been identified and were found to include genes whose products may function to potentiate the inflammatory response. We report that the expression signature for chronic TNF stimulation suggests a phenotype which promotes cell survival, while enhancing Th1 differentiation, recruitment to sites of inflammation and effector responses. We are now analysing data from experiments designed to explore the possibility that this particular gene expression signature is distinct from the programme of gene transcription arising from short term TNF stimulation. We anticipate that this approach may provide further insight into the molecular mechanisms which promote chronic, as opposed to acute inflammatory responses.
Methods: RA synovial fibroblasts were transduced using IL-10-or IL-1ra-encoding MFG retrovirus (multiplicity of infection (MOI) of 50-200) and/or Ad5 adenovirus (MOI of 10-50). Double gene transduction was performed in vitro in a co-culture approach with (a) retroviral IL-10 and IL-1ra, (b) adenoviral IL-10 and IL-1ra, (c) adenoviral IL-10 and retroviral IL-1ra, (d) retroviral IL-10 and adenoviral IL-1ra. Cytokine production was measured by ELISA. Expression of proto-oncogenes and cytokines before and after gene transfer was analyzed using a combination of RNA arbitrarily primed PCR (RAP-PCR) and cDNA expression array to determine virus-mediated molecular effects.
Results: IL-1ra and IL-10 overexpression performed either with retroviral or with adenoviral vectors resulted in an enhanced synthesis of these cytokines. Cytokine expression was substantially higher in adenovirally transduced than in retrovirally transduced fibroblasts (IL-1ra 317 vs. 39 pg/ml; IL-10 221 vs. 44 pg/ml). Double gene transfer of a combination of retrovirus-and adenovirus-encoded genes resulted in a predominant expression of the gene encoded by the adenovirus even when the retroviral transduction was performed first. Virus-related effects on gene expression using LacZ or EGFP were higher in adenovirus-(4% of the proto-oncogenes and cytokines) than in retrovirus transduced fibroblasts (2%).
Conclusions:
The results of the study demonstrate that combination of retro-and adenovirus-based vector systems for double gene transfer into RA synovial fibroblasts does not result in enhanced synthesis of the respective gene products but in suppression of the retroviral gene transfer. In addition, the experiments reveal that for human gene therapy the higher efficacy of adenovirus-based vectors needs to be outweighed against the lower effects on general alteration of gene expression when retrovirus-based vector systems are used.
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Family collections for the analysis of common autoimmune disease genes in systemic rheumatic and inflammatory diseases I Melchers, U Buchegger-Podbielski, A Feldmeyer, P Lodemann
University Medical Center Freiburg, Freiburg, Germany
At present, little is known about the influence of genetic factors on the appearance and development of human autoimmune diseases, including rheumatic and inflammatory diseases. Our aims are i) to provide the scientific community with the material required to study the genetics of these diseases, individually and in their relation to each other and ii) to contribute to these investigations. We therefore collected caucasian families with i) one index patient suffering from rheumatoid arthritis (RA), systemic scleroderma (SSc), relapsing polychondritis (rPC), Wegener's granulomatosis (WG) or Systemic Lupus Erythematosus (SLE), ii) at least one first degree relative suffering from the same or another rheumatic or autoimmune disease, iii) healthy first degree relatives. Blood samples from all family members were used to prepare and store plasma (or serum), DNA, and Epstein-Barr-Virus (EBV) transformed B cell lines. Clinical, immunological and genetic information of interest was documented in a database. Families of healthy people were collected for comparison. Up to now we have collected more than 100 families, mainly in Southwest Germany. According to the patient index there are now 59 with RA, 12 with SSc, 3 with rPC, 4 with WG and 24 with SLE. In addition we collected information and material from more than 200 patients with healthy relatives or unavailable families. In parallel we started to compare patients with "familiar" or "nonfamiliar" diseases and have already observed interesting differences. In patients with RA these differences concern sex distribution, the presence of rheumatoid factors and the age at disease onset. Introduction: Genetic factors that predispose individuals to ankylosing spondylitis (AS) are not fully understood. Axial and sacroiliac joint fibrosis are characteristic of AS and the presence of TGFβ1 mRNA in AS sacroiliac joints raised the possibility that this cytokine might be implicated in this fibrosis. We have therefore examined a group of HLA B27 positive AS patients to investigate whether they could be prone to fibrosis based on overproduction of TGFβ1. Methods: DNA from 132 AS patients, 113 healthy controls from the West of Scotland were compared. DNA covering the G/C polymorphic site at position +915 in the TGFβ1 gene was expanded by PCR and examined using sequence specific primers. Levels of mRNA from stimulated PBMC's from AS patients and controls were analysed using Taqman PCR. Serum TGFβ1 was measured by ELISA on acidified serum. Results: Although no significant differences in allele frequency was seen between these two populations examination of genotype frequencies showed that the AS patients were more likely to have the GG genotype associated with high TGFβ1 production (78% versus 64%; P < 0.01, OR=2.0. 95% CI 1.2-3.5). In keeping with this predisposition, the median level of TGFβ1 in serum from AS patients was 6359 pg/ml (range 3266-9587 pg/ml) which was higher (P < 0.02) than the controls (median 4903 pg/ml: range 136-7488 pg/ml). The levels of mRNA from AS patients were higher than controls. Conclusion: This is the first report of a link with a polymorphic site within the TGFβ1 gene in AS. An increased predisposition to high TGFβ1 production could provide insights into the aetiology to AS. Our data confirm that genes other than B27 may be involved in AS pathogenesis.
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The To ascertain if the polymorphism of HLA-DR, DQA and DQB alleles and QAP and QBP promoters influences the production of aCL and anti-β2-GP1 in SLE. While the role of HLA-antigens in directing various autoantibody responses is relatively well known, the effect of promoters is less established. Sixty-five consecutive unrelated Slovenian SLE patients (all female, mean age±SD 36±8.3 years, mean follow-up 93 months) and 74 unrelated healthy adults were investigated. aCL and anti-β2-GP1 were determined by ELISA. The patients and controls were typed for DRB1, DQB1, QAP and QBP alleles by PCR-SSO, using the 12th IHW primers, probes and protocols. The subtyping of DQB1 alleles as well as DQA1 typing was carried out with selected Dynal SSP primers. Allelic and deduced haplotypic frequencies in patients and controls were compared using Fisher's exact test. 32 (49%) and 16 (25%) of 65 SLE patients were positive for IgG, IgM and/or IgA aCL and anti-β2-GP1, respectively. The frequency of the DQB1*0202 allele was significantly higher in the aCL (P = 0.001) and anti-β2-GP1 (P = 0.001) negative patients than in controls. Conversely, the DQB1*0301 allele and its promoter QBP3.1 were underestimated in the aCL (P = 0.06) and anti-β2-GP1 (P = 0.001) negative patients compared with controls. The DQB1*0202 allele may have a preventive role in provoking autoimmune response against both tested aPL. While the DQB1*0301 allele and its promoter QBP3.1 were underestimated in anti-β2-GP1 negative patients, they did not seem to protect from β2-GP1 specific autoimmune response in SLE patients. In contrast, we have already observed positive correlation of anti-Ro antibody response with the DQB1*0202 allele and the significantly underestimated DQB1*0301 allele and its promoter QBP3.1 in the same group of anti-Ro positive SLE patients. (OA, n=3) . Specific sequences of galectin-3 cDNA were amplified by RT-PCR and used for the generation of digoxigenin-labeled riboprobes. In situ hybridisation was performed on paraffin sections. Immunohistochemistry was applied on paraffin and snap frozen sections using mouse monoclonal anti-galectin-3 antibodies. For comparison, the macrophage marker CD68 was used.
Results:
In RA, galectin-3 was found at sites of joint destruction, as well as in the lining and sublining layers. The percentage of positive cells, however, was lower in the lining than in the sublining layer. A predominant expression of galectin-3 was found in cells with follicle-like structures and in perivascular infiltrates, whereas vessels remained negative. Synovial fibroblasts also stained positive and, at least in the sublining, the expressions of galectin-3 and CD68 appeared mutually exclusive. In contrast, in OA synovial tissues, only a few cells in the lining layer were positive for galectin-3. Similar results were obtained by in situ hybridisation and immunohistochemistry. Conclusion: Taken together, theses observations suggest that galectin-3 is involved in cell-cell and cell-matrix interactions in the RA synovium and therefore may contribute to both the inflammatory and the destructive processes. SDF-1 (CXCL12), a CXC chemokine, has a primary role in signalling the recruitment of haematopoietic stem-cell precursors to the bone marrow during embryonic development. In post-natal life, SDF-1 is widely expressed and is induced in chronically inflamed tissues such as psoriatic skin and the rheumatoid synovium, but has also been implicated in the migration of lymphocytes to lymphoid organs. To investigate the role of SDF-1 in recirculation and homing in vivo we have developed a model in which human peripheral lymph nodes (huPLN) are transplanted into SCID mice. We have shown that huPLN transplants are viable and are vascularised by the murine circulation, forming functional anastomoses with transplant vessels. In addition grafts retain some of the histological features of the pretransplantation tissue, such as follicular dendritic cell-associated B-cell aggregates, lymphatic and HEV markers. We also show that SDF-1 is capable of inducing the migration of an SDF-1 responsive cell-line (U-937) and human PBL's from the murine circulation into the grafts in a dose dependant manner which is inhibitable by CXCR4 blockade. The mechanism of action of SDF-1 in this model is independent from that of TNF-α and does not rely on the upregulation of adhesion molecules (such as ICAM-1) on the graft vascular endothelium. This is the first description of huPLN transplantation into SCID mice, and of the functional effects of SDF-1 regarding the migration of human cells into huPLN in vivo. This model provides a powerful tool to investigate the pathways involved in cell-migration into lymphoid organs and potentially to target them for therapeutic purposes. The microvascular endothelium (MVE) plays a major role in inflammation as well as tumour growth. Thus, the MVE represents an important therapeutic target. Peptide phage technology has been used in vivo to discover peptide sequences with binding capacity to organ specific MVE determinants in animals. The application of such powerful technology to humans has been limited by the obvious difficulties of performing phage-screening studies in vivo. By grafting human tissues into severe combined immunodeficient (SCID) mice, it is possible to target specifically human MVE determinants. Here we report for the first time the identification of synovial specific homing peptides by in vivo phage display selection in SCID mice transplanted with human synovium. Selected synovial homing peptide-phages were found to bind to human synovial graft MVE and retain their tissue homing specificity in vivo independently from phage component, disease origin of transplants and degree of human/murine graft vascularisation. In addition, the selected phages demonstrate tissue and species specificity in comparison to cotransplanted human skin grafts or mouse vasculature. Sequence analysis of the peptide inserts from synovial homing phages identified recurrent consensus motifs. One such motif maintains synovial MVE specificity both when expressed by a single phage-clone and as a free biotinylated synthetic peptide. Furthermore, the free peptide competes and inhibits, in vivo, the binding of the original peptide-phage to the cognate synovial MVE ligand. The identification of synovial homing peptides, with tissue and species specificity, may allow the construction of targeting devices capable of concentrating therapeutic/diagnostic materials to human joints.
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Inmunohistologic analysis of synovial tissue from early and late osteoarthritic patients. A potential role for COX-2 and NF-κ κB1 (p50) regulation in early disease
MJ Benito, O FitzGerald, B Bresnihan
St Vincent's Hospital, Dublin, Ireland
Osteoarthritis (OA) is an erosive inflammatory disease originated by a biomechanical alteration that, in some patients, shows a strong component of inflammatory infiltrates in the synovial membrane resembling rheumatoid arthritis. T cells and macrophages initiate, amplify and perpetuate the inflammatory response. In stimulated cells, NF-κB, commonly formed by homodimers of NF-κB1 (p50), or heterodimers with RelA (p65) or c-Rel, bind to promoters and enhance, or occasionally inhibit, gene transcription through direct interaction with DNA. The activation of NF-κB may be a key step in the pathogenesis of OA. Inducible cyclooxygenase (COX-2) may also play a role in the inflamed profile, since it has a κB motive in its promoter. The aim of this study is to evaluate the differences in OA tissue, focusing on whether the pattern of NF-κB activation is quantitatively different in early and late stages, and its effect in COX-2 expression. Additional in vitro experiments, using OA cultured cells, were performed to evaluate the role of IL-6 and PGE2 in NF-κB activation and COX-2 induction. A significant increase in inflammatory cell infiltrate and hyperplasia of synovium was a feature found in early OA tissue. NF-κB1 and RelA were detected in all the OA samples studied, with significant increases observed in early OA tissue (P = 0.006 and P = 0.012). In concordance with NF-κB1/RelA, COX-2 expression was increased in early OA. Activation of p50 and p65 subunits of NF-κB showed a positive correlation with COX-2 (r=0.6169 and r=0.6620, respectively) and inverse correlation with COX-1 (r=-0.627 and r=-0.858) in early OA tissue, while only a positive correlation was observed between p50 and COX-2 in late OA (r=0.4129). In vitro synoviocytes cell cultures the activation of NF-κB in cells was observed together with an increase in COX-2 production. This activation was inhibited by parthenolide, an inhibitor of IκB degradation, and a concomitant decrease in COX-2 protein was observed as a result of the NF-κB inhibition. These findings support the conclusion that NF-κB and COX-2 play an important role in the early stages of OA, and specific inhibition could be a strategic approach in early OA. Objective: Serial synovial biopsy samples are increasingly used for the evaluation of novel therapies for rheumatoid arthritis (RA). Most studies have used knee biopsies, but technical improvements have made serial small joint arthroscopy feasible as well. Theoretically, there could be differences in the features of synovial inflammation between various joints as a result of mechanical factors, differences in innervation, and other factors. Therefore, we compared the cell infiltrate in paired synovial biopsies from inflamed knee joints with inflamed small joints obtained simultaneously in RA patients. Materials and methods: Nine RA patients with both an inflamed knee joint and an inflamed small joint (wrist or metacarpophalangeal) were subjected to an arthroscopic synovial biopsy of both joints on the same day. Multiple biopsy specimens were collected and stained for macrophages, T cells, plasma cells, fibroblast-like synoviocytes, and interleukin(IL)-6 by immunohistochemistry. Sections were analyzed by digital image analysis.
Results: The mean cell numbers for all investigated markers were equivalent in the samples from knee joints compared with the paired small joint samples. Statistical analysis by nonparametric tests identified no significant differences. Using Spearman Rank tests, we found significant correlations for the number of sublining macrophages (rho 0.817, P < 0.01), the number of T cells (rho 0.683, P < 0.05), and the number of plasma cells (rho 0.766, P < 0.02) when knee joints were compared with small joints. There was, however, no significant correlation for lining macrophages and fibroblast-like synoviocyte hyperplasia when large and small joints were compared.
Conclusion:
The results presented in this study show that inflammation in one inflamed joint is generally representative for the process in other joints. Therefore, it is possible to use serial samples from the same joint selecting either large or small joints for evaluation of antirheumatic therapies. Hyperplasia of the intimal lining layer due to accumulation of intimal macrophages and fibroblast-like synoviocytes appears to depend in part on local factors. Background: Fibroblast-like synoviocytes (FLS) express decayaccelerating factor (CD55) at high levels. One of its ligands, CD97, is a member of the EGF-TM7 family, a group of class B seven-span transmembrane receptors, which are prominently expressed by activated immune cells. Previous work has suggested a close association between CD55 + FLS and CD97 + intimal macrophages in rheumatoid arthritis (RA) synovium. These previous studies were performed with an antibody that binds both CD97 and EMR2, which is another member of the EGF-TM7 family. Recently, monospecific antibodies against EMR2 and CD97 were developed. Objective: To determine the expression of CD97 and EMR2 using novel, monospecific antibodies to provide more insight into the factors that might be involved in leukocyte activation in rheumatoid synovial tissue. Methods: Synovial tissue samples were obtained by arthroscopy from 19 RA patients, 17 inflammatory osteoarthritis (OA) patients, and 11 reactive arthritis (ReA) patients. Immunohistologic analysis was performed using the following antibodies: CLB-CD97/1 (which recognizes both CD97 and EMR2), CLB-CD97/3 (specific for CD97), and 2A1 (specific for EMR2). Bound antibody was detected according to a 3-step immunoperoxidase method. In addition, double immunofluorescence was performed. Stained sections were analyzed by digital image analysis using a standardized program and compared by nonparametric statistical analysis.
Results: CD97 was shown to be expressed on activated leukocytes in the intimal lining layer and in the synovial sublining in all forms of arthritis. Of interest, we observed a specific increase in the expression of EMR2 positive cells of myeloid lineage in RA compared with ReA and OA synovium, even after correction for cell numbers. These differences were statistically significant (RA versus ReA and OA for both lining and sublining: all P values < 0.03). Double immunofluorescence revealed that 40-60% of the macrophages in RA synovium expressed EMR2.
The increased expression of various members of the EGF-TM7 family in inflamed synovial tissue suggests a role in the formation of the architecture of the intimal lining layer as well as in the maintenance and amplification of synovial inflammation. EMR-2 might be involved in the specific activation of macrophages in RA. Objective: Overexpression of the nuclear autoantigen hnRNP-A2 (RA33) has recently been observed in synovial tissue of RA patients and TNF transgenic mice. To further investigate this issue expression of hnRNP-A2 was compared with that of two other hnRNP proteins, the closely related hnRNP-A1 (a rare autoantigen in RA) and the structurally different hnRNP-C (which is not an autoantigen). In addition, expression of the tumour suppressor p53 and the MAP-kinase p38 was studied. Methods: Synovial tissue of patiens with RA or osteoarthitis and specimen from patients with early arthritis of <1 year duration were analyzed by immunohistochemistry Results: HnRNP-A2 was highly overexpressed in RA synovial tissue as compared to tissue of osteoarthritis patients, and most abundantly found in CD68-positive cells of the lining layer. The antigen was not only localized in the nucleus but also in the cytoplasm confirming previous observations. Nuclear overexpression was also observed for hnRNP-C, whereas expression of hnRNP-A1 appeared normal. Remarkably, in the majority of hnRNP-A2 expressing cells also the p53 tumor suppressor was overexpressed and aberrantly localized in the cytoplasm. Furthermore, the MAP-kinase p38 was acitvated in these cells as revealed by a monoclonal antibody specifically recognizing the phosphorylated (activated) form of this kinase. Aim: To dissect the role of the endogenous, cytokine-like protein high mobility group 1 protein (HMGB1) in arthritis, we set out to investigate the presence of HMGB1 in synovial biopsies from rats with adjuvant arthritis and in synovial biopsies and synovial fluid samples from patients with active RA. Background: HMGB1 is a DNA-binding, non-histone, nuclear protein present in all nucleated cells. Previous results have demonstrated that HMGB1 is released from the cytoplasm of activated monocytes and macrophages and that extracellular HMGB1 is a potent inducer of production of proinflammatory cytokines in monocytes and macrophages. Furthermore, anti-HMGB1 treatment inhibits LPS-induced lethality in sepsis in mice. Methods: Presence of released HMGB1 in synovial membranes from arthritic rats and synovial membrane biopsies from RA patients, were detected by immunohistochemistry. Analysis of HMGB1 in synovial fluid was performed by western blotting. Results: In rat ankle joint specimens obtained at the onset of arthritis, as well as in the chronic stage of the disease, we detected cytoplasmic HMGB1 in macrophage/monocyte-like cells in the synovial membrane as well as in synovial fluid. The levels of cytoplasmic expression was higher at later stages of disease. A similar picture was obtained when immunohistochemical stainings were performed on synovial biopsies from RA patients. Analysis of synovial fluid samples from RA patients revealed high levels of released HMGB1. Intra-articular rHMGB1 injections in rats caused erosive synovitis. Conclusion: HMGB1 is a newly identified proinflammatory molecule, now shown to be present in arthritic joints of both RA patients and rats with adjuvant arthritis. With reference to the previously demonstrated capacity of HMGB1 to stimulate the production of TNF and IL-1β, we speculate that HMGB1 could be of importance in the pathogenesis of arthritis.
40
Expression of protease-activated receptors in arthritic synovial tissues AK So, V Chobas-Péclat, C Morard, N Busso
Service de Rhumatologie, Lausanne, Switzerland
Clinical and experimental evidence suggests that synovial thrombin formation in arthritic joints is prominent and deleterious, leading to exacerbation of rheumatoid arthritis (RA). In this context, cellular effects of thrombin mediated by the protease-activated receptors (PARs) in arthritic joints may be of paramount significance. Four PARs have now been identified. PAR1, PAR3, and PAR4 can all be activated by thrombin whereas PAR2 is activated by trypsin and few other proteases. We first explored PARs expression in RA synovial tissues. Synovial membranes from 11 RA patients were analyzed for PARs expression by RT-PCR and by immunohistology. PAR4 was found in all the biopsies, whereas the expression of PAR1, PAR 2 and PAR3 was more restricted (8/11, 5/11 and 3/11 respectively). In the arthritic synovial membrane of murine antigen-induced arthritis (AIA) we found coexpression of the four different PARs. Next, we explored the functional importance of PAR1 during AIA in vivo using PAR-1 deficient mice. The phenotype of PAR1-deficient mice (n=22), based on the analysis of arthritis severity (as measured by 99 m tecnetium uptake, histological scoring and intra-articular fibrin measurements) was similar to that of wild-type mice (n=24). In addition, the in vivo production of antibodies against mBSA was also similar. By contrast, the mBSA-induced in vitro lymph node cell proliferation was significantly decreased in PAR1-deficient mice as compared with controls. Accordingly, mBSA-induced production of interferon-γ by lymph node cells in culture was significantly decreased in PAR1-deficient mice as compared with controls, whereas opposite results were observed for production of IL-10.
IFN-β β-induced IL-1Ra synthesis in human monocytes involves PI 3-kinase-STAT1 signaling pathway J-M Dayer, N Hyka, M-T Kaufmann, R Chicheportiche, D Burger
*University Hospital, Geneva, Switzerland
IFN-β displays an anti-inflammatory property by inducing IL-1Ra without triggering synthesis of IL-1β in human monocytes (Mo). IFN-β initiates JAK-STAT pathway that may cross-talk with components of MAP-and PI 3-kinase pathways. Since maximal activation of transcription by several STATs requires both Tyr and Ser phosphorylation, we investigated the role of MAP-(ERK1/2) and PI 3-kinases in IFN-β-induced IL-1Ra production in Mo. The PI 3-kinase inhibitor Ly294002 but not the MAP kinase inhibitor PD98052 suppresses, in a dosedependent way, IL-1Ra production in Mo at a protein level correlating with the reduction of steady state levels of IL-1Ra mRNA. IFN-β treatment of Mo leads to rapid Ser-phosphorylation and nuclear translocation of STAT1 that is inhibited by Ly294002. Interestingly, suppression of PI 3-kinase activity in Mo stimulated by IFN-β and antiCD11b mAb results in inhibition of IL-1Ra and upregulation of IL-1β production, suggesting that PI 3-kinase might be a check-point signaling molecule favoring IL-1Ra synthesis. Involvement of PI 3-kinase pathway in IL-1Ra synthesis seems to be independent of the differentiation state of Mo: M-CSF differentiated Mo requires activation of PI 3-kinase to synthesize IL-1Ra following IFN-β treatment. Thus, IFN-β induced IL-1Ra production in Mo by simultaneously activating components of JAK-STAT and PI 3-kinase signaling pathways.
destruction, seen in various murine models of arthritis mediated by immune complexes (IC). In the mouse, two activating FcγR (FcγRI and FcγRIII) which bind IC have been described. In this study, we investigated the role of activating FcγRIII in MMP-mediated cartilage destruction in two different models of experimental arthritis, one induced only by ICs and the second by ICs and T cells. Methods: Mice made deficient for FcγRIII and their wildtype controls(C57BL/6) were used. Immune complex arthritis (ICA) was induced by injecting lysozyme directly into the knee joint of mice, which had previously been given antilysozyme intravenously. T cellmediated IC-mediated IC-arthritis (AIA) was induced by immunizing mice with mBSA in CFA and injection of the antigen directly into the knee joint, 3 weeks after immunization. Cartilage destruction was studied by immunolocalisation of MMP-mediated neoepitopes (VDIPEN) and matrix erosion in total knee joint sections. Adaptive cellular cells (T cells) and humoral immunity (anti-mBSA antibodies) were investigated using lymphocyte stimulation assay and ELISA.
Results: ICA induced in naive C57BL/6 knee joints showed florid inflammation at day 1 and 3. MMP-mediated cartilage destruction and matrix erosion was moderate at day 3. When ICA was induced in knee joints of FcγRIII deficient mice, joint inflammation, MMPmediated cartilage destruction and erosion was significantly lower (respectively 95, 100 and 80% In a recent report, we suggested the implication of a phosphoinositide-3 kinase (PI3 kinase) pathway in IL-18-induced VCAM-1 expression in rheumatoid arthritis (RA) synovial fibroblasts. Here, we demonstrated for the first time that IL-18 rapidly activates PI3 kinase and its downstream effector Akt. In our investigation to elucidate the signaling events downstream and upstream of PI3-kinase, we found that IL-18 induces a parallel pathway involving extracellular regulated kinases (ERK) 1/2. Using specific kinases inhibitors LY294002 and PP2, we showed that ERK1/2 activation was independent of PI3 kinase but dependent of Src kinase with an approximately 63% (P < 0.05) decrease of phosphorylated ERK. IL-18 also showed a time dependent activation of both c-Src, Ras and Raf-1suggesting the implication of this signaling cascade in ERK activation. Electrophorectic mobility shift assay demonstrate that activator protein-1 (AP-1) is activated by IL-18 through ERK and Src but not through PI3 kinase. Finally, the Src kinase, which is known to activate PI-3 kinase may represent the early event in IL-18-activated PI3 kinase because the specific inhibitors of these two kinases both affect IL-18 induced VCAM-1 expression in RA synovial fibroblasts by 50% (P < 0.05). In contrast, PD98059 and pertussis toxin had no impact on VCAM-1 expression excluding the participation of ERK and Go/i proteins in the IL-18-mediated VCAM-1 production. These data demonstrate the activation of two novel pathways in IL-18-stimulated RA synovial fibroblasts and they indicate that it is possible to selectively inhibit the expression of VCAM-1. Targeting PI3 kinase may represent an interesting approach to the development of selective drugs in inflammation and RA. Results: RWJ-67657 induced a dose-related decrease in IL-6, IL-8 and MMP-3 production, both after IL-1β and TNF-α stimulation. Inhibition of MMP-1 was seen only at high levels of RWJ-67657. TIMP-1 was produced constitutively and was not affected by stimulation or inhibition. These findings were all confirmed by mRNA expression studies. COX-2 mRNA expression was induced both by IL-1β and TNFα and could be inhibited by RWJ-67657. ADAMTS-4 mRNA expression was only seen after IL-1β stimulation, which could be inhibited by RWJ-67657. Conclusion: RWJ-67657 is a potent inhibitor of cytokine and MMP production, as well as of their mRNA expression in stimulated RA synovial fibroblasts. Also COX-2 and aggrecanase mRNA expression was inhibited by RWJ-67657. Thus, inhibition of the p38 MAPK pathway by RWJ-67657 effectively leads to inhibition of different inflammatory mediators produced by rheumatoid synovial fibroblasts. Therefore, RWJ-67657 could be of therapeutic significance in RA. Rheumatoid arthritis (RA) is characterized by hyperplasia of the synovium and degradation of cartilage by fibroblast-like synoviocytes (FLS). The hyperplasia is thought to be a result of an imbalance between proliferation and apoptosis. Proliferation and apoptosis can be regulated by death receptors like TNF receptor and Fas. TNF is abundantly expressed in the rheumatoid synovium and could contribute to the hyperplasia by promoting proliferation and/or inhibition of apoptosis. In this study it was investigated whether overexpression of flice inhibitory protein (FLIP), a protein that inhibits death receptor mediated apoptosis, could potentially be involved in the hyperplasia of FLS. Epression of FLIP was investigated using a western blot and was seen in all samples tested, but most expression was seen in two trauma patients (n=3), one OA patient (n=2) and two patients with prosthesis loosening (n=3). RA patients (n=3) showed the least expression of FLIP (see figure 1 ). Thus, in RA FLS no overexpression of FLIP was observed, therefore it is unlikely that FLIP contributes to resistance to apoptosis of FLS and hyperplasia in the rheumatoid synovium.
47
Chronic exposure to TNF activates distinct TNF-R signaling pathways favouring cell survival in T lymphocytes AP Cope, P Vagenas, M Panesar, JM Clark
Kennedy Institute of Rheumatology, London, United Kingdom
Tumour necrosis factor α (TNF) is a multipotent cytokine. Its role in the pathogenesis of rheumatoid arthritis (RA) is now well established. However, the signaling pathways activated by TNF in the context of chronic inflammation are less well understood. We have previously reported that chronic as opposed to acute TNF exposure induces non-deletional and reversible T cell hyporesponsiveness to T cell receptor ligation. To explore this further, we set out to explore more precisely how TNF signals in T lymphocytes, and in particular to determine whether chronic exposure to TNF activates a cascade of signaling pathways which are qualitatively or quantitatively distinct from those activated following short term stimulation. Initial experiments revealed that the p55 TNF-R is necessary and sufficient to induce T cell hyporesponsiveness. Accordingly, we focussed subsequent studies on p55 TNF-R signaling in a murine T cell hybridoma model. Over 8 days, repeated stimulation of T cells with pM doses of TNF leads to chronic, stable cytokine exposure throughout the culture period. At this low dose NF-κB is activated, while activation of other p55 TNF-R signaling pathways is much less pronounced. Within minutes of TNF-R ligation, high dose (nM) TNF induces strong activation of NF-κB and JNK in
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Figure 1
Western blot showing expression of human FLIP in several patients. #, Trauma patients; RA, rheumatoid arthritis; PL, prosthesis lossening patients.
control T cells. In contrast, TNF-R ligation of T cells chronically exposed to low dose TNF leads to attenuation of JNK activation, while activation of NF-κB and ERK are spared. Preliminary data indicate that translocation of RelA to the nucleus is enhanced and sustained in TNF treated T cells. Together, the data indicate that the signaling pathways in T cells exposed to inflammatory cytokines for prolonged periods may be distinct from those activated by cytokines over much shorter periods. We speculate that in diseases such as RA, T cell effector responses may be promoted by selective activation of the ERK and NF-κB pathways, which promote T cell survival. The data also predict that the gene expression signature arising from chronic TNF stimulation should be distinct from the programme of gene transcription arising from short term TNF-R engagement. We recently demonstrated that expression of the zeta chain of the TCR (TCR zeta) was down-regulated in TNF-treated T cells. Reduced expression of TCR zeta, together with impaired assembly and stability of the cell surface TCR/CD3 complex, may uncouple proximal signal transduction pathways from the TCR. We have proposed that signalling pathways downstream of the TCR may be attenuated as a result, and that this may contribute to the hyporesponsive phenotype. A T cell hybridoma cell line was generated which expressed a single-chain Fv/TCR zeta chimaeric receptor (C2-zeta) under control of retroviral LTR: TNF was not expected to affect expression of C2-zeta. We now report that the receptor-proximal tyrosine phosphorylation responses of these cells were reduced after prolonged TNF-treatment, even though C2-zeta expression was unchanged. Furthermore, while the amplitude and duration of calcium release from intracellular stores were slightly lower in TNFtreated T cells, there was a marked attenuation of capacitative calcium entry in these cells. In addition, PMA-and ionomycin-stimulated IL-2 production was also suppressed in cells that had undergone prolonged culture in TNF. Estrogens have been recognized for many years for their positive effects on bone. However, their mechanisms of action are still only partially resolved. Although it is generally accepted that estrogens act at genomic level by binding to intracellular estrogen receptor, they trigger nongenomic effects mediated by plasma membrane receptor. One of these is to increase activity of the BK channel in many cells types (smooth muscle and vascular endothelium), but this has never been reported in bone. BK channels are composed of alpha (encoded by Slo gene) and beta subunits. The alpha subunit forms the K+/-selective pore, while beta subunits influence the pharmacology, kinetics, and voltage/calcium sensitivity of the BK channel. β1 and β4 subunits have been reported to mediate estrogen effects on the BK channel. In this study, we have shown that primary human osteoblasts, and 3 cell lines of human osteosarcoma (MG63, SaOs2, CAL72) express the Slo protein (western blot). Using RT-PCR, we observed in all these cells the expression of the 4 beta subunits (β1, β2, β3, β4). In electrophysiology analysis, we observed a calcium-induced potassium current of high conductance. As expected, β1 subunit expression induced Charybdotoxine and Iberiotoxine (classical inhibitors of the BK channel) resistance of the BK channel. We investigated whether 17β estradiol increased the probability of the BK channel opening (NP0). Our data indicate that 17β estradiol (5 nM) increase BK channel activity, shedding a new light on the nongenomic effects of estrogens and opening new ways for therapeutic development. 
University of Erlangen-Nuremberg, Erlangen, Germany
Polyamines (PAs) are involved in regulation of cell growth and cellular survival by interacting with processes like translation, transcription or ion transport. It is described that polyamines can induce apoptosis in mesenchymal cell lines. The aim of our study was to analyze whether the physiological PAs (putrescine, spermidine or spermine) or the PA-derivate deoxyspergualin (DSG), a novel immunosuppressant, induce apoptosis in immunocompetent cells. Furthermore, we wanted to investigate which molecular mechanisms are involved in the execution of the cell death program. By means of flow cytometric analysis we found an induction of apoptosis by spermine (Spm) and DSG in quiescent and activated PBMCs, PHA generated lymphoblasts, and various tumor cell lines (Jurkat, SKW-3, U937). Moreover, DSG and Spm triggered apoptosis in human Fas-deficient cells and in cell lines MV 4.11. and RS 4.11., which are described to be resistant to apoptosis induction by many conventional chemotherapeutic agents. Apoptosis induction after Spm or DSG treatment was dependent on caspase activity and associated with a decrease in mitochondrial membrane potential and Bcl-2 expression. In order to test whether PAs mediate their proapoptotic effects through metabolites resulting from PA catabolism, we tested different antagonists of PA degrading enzymes or PA metabolites. We show that aminoguanidine (inhibition of PA oxidase), aldehyd-dehydrogenase (degradation of PA-aldehydes) or N-acetyl-cystein (prevention of PA-induced glutathion depletion) prevented PA-mediated apoptosis. Acrolein, and PA-related aldehyde, could induce programmed cell death in our system. We conclude that PA aldehydes and PA-triggered glutathion depletion cause apoptosis in immunocompetent cells and apoptosis-resistant tumor cell lines.
Cytokines
TRAIL-mediated enhancement of collagen production by human lung fibroblasts VV Yurovsky
University of Maryland, Baltimore, Baltimore, MD, USA Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that induces apoptosis in a variety of transformed cell lines and in normal human hepatocytes in vitro. The expression of TRAIL was found in CD8 T cells that had undergone oligoclonal expansion in the lungs of patients with systemic sclerosis (scleroderma) and were able to stimulate collagen production in lung fibroblasts in vitro. Among the family members, TRAIL displays highest homology to CD95 ligand, a receptor of which may not only mediate apoptosis of T cells, but also mediate the proliferation of normal human fibroblasts. Considering structural and functional similarities between TRAIL and CD95 ligand, we examined the effects of soluble TRAIL on normal human lung fibroblasts. Collagen α2(I) mRNA expression was assessed by real-time RT-PCR, with ribosomal protein S9 as an internal standard. Total soluble collagen was measured in culture supernatants using the Sircol Biocolor Assay. Both normalized α2(I) collagen mRNA expression and total soluble collagen secretion were increased upon TRAIL stimulation, with peak response (>5-fold increase) at 10 ng/ml TRAIL. DNA microarray hybridization revealed 78 genes involved in signal transduction, DNA transcription, and tissue remodeling, whose expression level increased, and 8 genes whose expression level decreased >2.5-fold in comparison with quiescent fibroblasts. Augmented expression of a number of genes involved in the TGFβ pathway suggested that TRAIL might induce TGFβ-mediated autocrine and/or paracrine stimulation of fibroblasts. This was confirmed by the ability of anti-TGFβ antibody to inhibit the effects of TRAIL on collagen production by fibroblasts. DNA mobility shift assay also revealed TRAIL-induced increase in protein binding to the collagen promoter that was substantially inhibited by consensus oligonucleotide for Smad3/4, mediators of TGFβ signaling. These data suggest that TRAIL can enhance extracellular matrix synthesis in fibroblasts by triggering TGFβ production, which acts in autocrine manner. Rheumatoid arthritis (RA) can be considered as an ectopic lymphoid organ. This suggests a role for chemokines in the migration of T lymphocytes and dendritic cells (DCs) leading to the local organization that is characteristic of the follicular structure of RA synovium. To clarify whether DCs reach the synovium as mature cells or undergo local maturation, we characterized, by immunohistochemistry, the different DC subsets and their association with IL-17 and IFN-γ-producing T cells. The study was done in 12 RA synovium using tonsils as positive control. Immature and mature DCs were defined by expression of CD1a and DC-LAMP/CD83 respectively. Immature CD1a + DCs were mainly detected in the lining layer whereas mature DCs were exclusively detected in the perivascular or lymphocytic infiltrates. The lack of coexpression of DC-LAMP and CD1a indicated the presence of independent immature and mature DC subsets. IL-17 and IFN-γ-producing T cells were detected at the periphery of the lymphocytic infiltrates. They had a plasmacytoid-like appearance but staining for immunoglobulin light chains was negative. A similar morphotype was also observed in stimulted PBMC. To define the DC and Th1 lymphocytes migration pattern, we focused on the expression of chemokines and their associated receptors CCL20/CCR6 controlling the migration of immature DCs and activated T lymphocytes, and CCL21/CCR7, CCL19/CCR7 involved in mature DC and T lymphocyte homing. CCL20 was expressed in the lining layer and to a lower extent in the lymphocytic aggregates. CCL20 colocalized with its receptor CCR6. CCL20-producing cells were associated with CD1a+ immature DCs or IL-17-producing T cells, suggesting the contribution of CCL20 to the homing of CCR6+DC and CCR6+Th1 cells to RA synovium. CCL21 and CCL19 were only detected in the perivascular aggregates as observed for their receptor CCR7. Close association between CCL19, 21, CCR7, and mature DCs or IL-17-producing T cells argues for a role for these chemokines in the homing of CCR7+ DCs and CCR7+IL-17-producing T cells in perivascular infiltrates. We conducted a study testing the hypothesis that IL-18 predicts disease activity in patients with rheumatoid arthritis (RA), as measured by the number of swollen joints (40 joint counts), DAS28, the sedimentation rate and bone erosion. The study consisted of 57 patients with RA and 20 control subjects. The mean age of the patients was 51 years (range 29 to 75 years). The duration of the disease averaged 7.3 years (range 0 to 30 years). The numbers (means) of swollen and tender joints were 5.2 and 5.5 respectively. The mean activity disease score (DAS28) averaged 4.9 (range 0.6 to 11). Methotrexate and systemic glucocorticoids were administered to 40% and 30% of the patients, respectively. IL-18 was significantly increased in RA patients as compared to controls. The plasma concentration of IL-18 averaged 231 and 144 pg/ml in RA patients and controls (P < 0.001). DAS28, CRP, sedimentation rate and IL-18 positively correlated with the plasma IL-1Ra concentration (P < 0.001, P < 0.001, P < 0.001 and P < 0.002), respectively. Stepwise backward and multiple regression analyses demonstrated that the plasma concentration of IL-1Ra correlated positively with sedimentation rate, serum triglycerides and bone erosion (r=0.74; P < 0.001). Plasma IL-18 correlated positively with CRP (r=0.36; P < 0.007) and IL-1Ra (r=0.42; P < 0.002) but not with the overall disease activity (DAS 28) or bone erosions. Striglycerides correlated positively with IL-1Ra and IL-18 (P < 0. The IL-6 family member Oncostatin M (OSM) is expressed in the joints of rheumatoid arthritis patients. Murine OSM was expressed in the joints of naive wild-type mice by an adenoviral vector (AdmuOSM). This induced inflammation. Gene expression for IL-1, IL-6 and TNF-α were greatly enhanced in the inflamed synovium.
To determine the role of these cytokines in the AdmuOSM induced inflammation, we injected this vector in IL-1, IL-6 or TNF-α knockout (ko) mice. Both IL-1 and TNF-α ko mice showed reduced acute inflammation. Inflammation at day 14, however, was not reduced compared to wild-type mice. AdmuOSM induced inflammation in IL-6 ko mice did not differ from wild-type inflammation. In all the mice examined, cartilage proteoglycan depletion occurred. Depletion of proteoglycans not only occurred in the articular, but also in the epiphyseal cartilage. Early during the inflammation, the periosteum became activated and new bone apposition took place along the femur and tibia. These results suggest an important and independent role for OSM in joint pathology. Furthermore, they show that overexpression leads to damage to the epiphysis and bone apposition.
Effect of IL-18 on synovial cell subsets and its regulation by IL-18BP M Kawashima, P Missec
INSERM U403, Lyon, France
IL-18 has multiple biological activities that are important in generating Th1 responses and inflammatory tissue damage. IL-18 has molecular similarity with IL-1, and IL-18 receptor (IL-18R) belongs to the superfamily of IL-1 receptor. In our previous studies, IL-18 was detected in both synovial fluid and serum samples from patients with rheumatoid arthritis (RA) and serum IL-18 levels correlated with disease activity as assessed by levels of serum CRP and erythrocyte sedimentation rate. We then examined the synovial expression of IL-18 in RA. Isolated RA tissue cells could spontaneously produce high amounts of IL-18 in culture. In RA synovium, IL-18-positive cells were frequently located in both the lining and sublining layer, but not in lymphocyte aggregates. Both CD14 + macrophages and synoviocytes isolated from RA synovium expressed detectable levels of IL-18 mRNA. Using IL-1 as a positive control, we next examined the effect of IL-18 on IL-6 production in RA synoviocyte culture. In contrast to IL-1, IL-18 has no effect on IL-6 production from RA synoviocyte at both mRNA and protein levels. This lack of response appears to be related to defective receptor expression. 
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The expression of IFN-β β in synovial tissue from rheumatoid arthritis patients compared to osteoarthritis and reactive arthritis patients J van Holten, TJM Smeets, MC Kraan, PP Tak
Academic Medical Center, Amsterdam, The Netherlands
Objective: IFN-β may have anti-inflammatory effects in rheumatoid arthritis (RA) patients through inhibition of the production of proinflammatory cytokines like TNF-α. Increased IFN-β production in RA synovium could represent a reactive attempt to inhibit the inflammatory cascade. The aim of this study was to determine the expression of IFN-β in synovial tissue of patients with RA, osteoarthritis (OA), and reactive arthritis (ReA). Methods: Synovial biopsy specimens were obtained by needle arthroscopy from 15 RA patients, 10 patients with inflammatory osteoarthritis (OA), and 5 patients with reactive arthritis (ReA).
Immunohistologic analysis was performed using a monoclonal antibody specific for IFN-β (PBL). Bound antibody was detected according to a 3-step immunoperoxidase method. Stained sections were evaluated by computer-assisted image analysis. Results: IFN-β was abundantly expressed in the synovial tissue of RA patients, especially by fibroblast-like synoviocytes. Digital image analysis using a standardized program revealed a statistically significant increase in the mean integrated optical density for IFN-β expression in RA synovial tissue compared with controls (RA 1900±514 vs. OA 447±171, and ReA 358±195) (P < 0.04). The specific upregulation of IFN-β expression was also observed when the results were controlled for cell numbers (P < 0.02).
Conclusions:
The increased expression of IFN-β in RA synovium suggests activation of an immunomodulatory mechanism that could inhibit synovial inflammation.
BiP may have an immunoregulatory function mediated through IL-10 production VM Corrigall, MD Bodman-Smith, GS Panayi
GKT School of Medicine, London, United Kingdom
Aim: We have recently described BiP, a ubiquitous chaperone protein and member of the heat shock protein 70 family, as an autoantigen in rheumatoid arthritis (RA). Animal studies showed that pretreatment with BiP conferred protection from adjuvant arthritis in rats and collagen induced arthritis in mice. Methods: Peripheral blood mononuclear cells (PBMC) were stimulated with recombinant human (rhu) BiP, rhu β-galactosidase (β-gal) and lipopolysaccharide (LPS) in the presence or absence of polymyxin B (polyB). Supernatants were collected after 24 hours and IL-10, TNF-α, IL-1β were measured by ELISA. Proliferation was measured by uptake of tritiated thymidine following stimulation of PBMC by tuberculin PPD in the presence and absence of BiP at 5 days. Results: BiP induced production of IL-10 was significantly higher than that induced by β-gal (P = 0.008) and LPS (P = 0.033). Polymyxin B caused no inhibition of cytokine release following rhu BiP stimulation (-polyB: 4.8±1.5 ng/ml vs. +polyB: 4.6±1.6 ng/ml) although IL-10 secretion by rhu β-gal (-polyB: 4.3±1.1 ng/ml vs. +polyB: 1.7±0.4 ng/ml) and LPS (-poly B: 3.2±0.8 ng/ml vs. +polyB: 1.6±0.7 ng/ml) was significantly reduced. BiP stimulation induced TNF-α production at a lower concentration than IL-10 and none was detectable 96 hours post-stimulation. The proliferative response of PBMC to tuberculin PPD was significantly reduced by the presence of BiP (P = 0.0128).
Conclusions:
The increased production of IL-10 induced by rhu BiP stimulation was not due to LPS contamination of the recombinant protein. BiP may have an immunoregulatory role mediated through the production of IL-10.
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The human chaperone BiP stimulates interleukin(IL)-10 producing CD8 T cells: implications for rheumatoid arthritis MD Bodman-Smith, VM Corrigall, DM Kemeny, GS Panayi
GKT School of Medicine, London, United Kingdom
Introduction: Rheumatoid Arthritis (RA) is the most common, crippling autoimmune disease, affecting between 0.3 and 3% of the population. Our laboratory has implicated the human chaperone, BiP, in the disease process. Aims: This study was aimed at dissecting the T cell response to BiP. Methods: T cell clones from normal individuals shown to respond to BiP were generated. The specificity of the clones was determined and the clonality determined by staining for the Vβ region of the T cell receptor. Supernatants were taken from the clones and control cells after stimulation with phytohaemagglutinin and cytokine production determined by ELISA. Additional phenotypic investigation was performed by flow cytometry. Results: Out of the 6 clones isolated, which responded to BiP, 5 expressed CD8 and 1 CD4. Three clones, all CD8 + , grew strongly and were investigated further. T cell receptor usage was determined in two clones (Vβ 7.1 and Vβ 12) with the Vβ element of the remaining clone not being recognised by the panel of antibodies used. All three clones produced IL-10 (80-380 pg/ml), with two producing IL-4 (10-80 pg/ml) and IL-5 (>5000 pg/ml). One clone produced both IL-10 and IFNγ (>5000 pg/ml). Additional phenotyping of these clones showed them to express CD25, CD28, CD80 and 86 but not CD56 or 57. One clone constitutively expressed CTLA-4 cytoplasmically.
Conclusions:
This study shows that a population of CD8 + T cells, with the cytokine profile of Tc2 cells, can be stimulated by the chaperone BiP. These cells may perform a regulatory role in the normal response to inflammation. The increase in response to this antigen in the synovial joint in RA may indicate an attempt to regulate the ongoing inflammation. Methods: DBA/1 male mice with collagen induced arthritis (CIA) were treated with daily intraperitoneal injections of IFN-β (2.5 mg/day, 1.25 mg/day, 0.25 mg/day), or NaCL for 7 days (n=8-10). Treatment started on day 1, which represents the first day that clinical arthritis was detected in that mouse. The mice were sacrificed on day 8. Immunohistologic staining was performed on decalcified wax-embedded paw sections with polyclonal antibodies specific for TNF-α, IL-1β, IL-6, IL-10, and IL-18. The sections were evaluated by semiquantative analysis on a 5-point scale (0-4).
Results: There was a statistically significant decrease in the mean scores for expression of TNF-α and IL-6 in animals treated with the highest dose of IFN-β (2.5 mg/day) compared with the NaCL control group (TNF-α: NaCL: 2.9±0.3 vs. IFN-β 1.4±0.2) (IL-6: NaCL: 2.3±0.3 vs. IFN-β 0.9±0.3) (TNF-α: P < 0.05, IL-6: P < 0.05). IL-18 and IL-1β expression tended to be lower in IFN-β treated animals, but this difference did not reach statistical significance. Interestingly, IL-10 production was increased in the IFN-β treated animals (NaCL: 0.5±0.3 vs. IFN-β: 1.6±0.5), although not statistically significant.
Conclusion:
The reduced expression of TNF-α, IL-6, IL-1β, and IL-18 and the increased expression of IL-10 in mice with CIA treated with IFN-β extends previous in vitro observations. Because of its immunomodulatory effects, IFN-β is a potential therapy for RA. IL-1 receptor antagonist (IL-1Ra) is a member of the IL-1 family, which acts as a natural IL-1 inhibitor. The balance between IL-1 and IL-1Ra plays an important role in the course of various inflammatory diseases, such as arthritis. IL-1Ra is produced as different isoforms, one secreted (sIL-1Ra) and three intracellular (icIL-1Ra1, 2, 3), derived from the same gene. We examined the production of IL-1Ra isoforms by cultured human articular chondrocytes in response to various cytokines. The concentrations of IL-1Ra were measured by ELISA in conditioned media and cell lysates. The levels of IL-1Ra were undetectable in culture supernatants of untreated cells, but were significantly increased by IL-1β (IL-1). IL-1Ra secretion was first detectable after 24 hours and increased progressively thereafter, for at least 72 hours. In contrast, the cell lysates contained very low levels of IL-1Ra, even in response to IL-1 stimulation, suggesting that articular chondrocytes produce essentially the sIL-1Ra isoform. IL-6, which had no effect on its own, enhanced the effect of IL-1, while dexamethasone (dex) prevented the response. By RT-PCR, we observed that IL-1 and IL-6 induced mainly the production of sIL-1Ra mRNA. Furthermore, IL-1 alone or combined with IL-6 increased the levels of nascent unspliced sIL-1Ra mRNA, suggesting that sIL-1Ra expression is regulated at the transcriptional level. Consistently, reporter gene assays performed in immortalized human chondrocytes, C20/A4, showed increased sIL-1Ra promoter activity in response to IL-1 and IL-6. In conclusion, human articular chondrocytes produce sIL-1Ra in response to IL-1. This effect, which is enhanced by IL-6 and inhibited by dex, reflects increased transcription from the sIL-1Ra promoter. The production of sIL-1Ra by chondrocytes may have a protective effect against articular inflammatory and catabolic responses. Introduction: It is well known that intra-articular steroids are efficient and fast in reducing arthritis symptoms. However, treatment does not exclude long-term morbidity. Earlier studies have shown individual patterns in cytokine expression both inherently and in response to treatment. In this study we investigated the effect of ia steroids on the synovial tissue before and 10 days after treatment.
Patients and methods:
Serial arthroscopical synovial biopsies were taken from patients with knee arthritis, before and ten days after ia triamcinolone injection. Biopsies were stained for histology, cytokines, cellmarkers and adhesion molecules using monoclonal antibodies, and measured by digital analysis or conventional counting of cells. Statistics were performed by Wilcoxon paired t-test. Results: Almost all patients (10/11) improved clinically and macroscopically by arthroscopy. Only ICAM-1 and CD3 were significantly reduced. Very small amounts of TNF-producing cells were observed with a clear trend of reduction, but individual patterns were observed. No overall changes were observed for CD68/163, IL-1α or IL-1β. Conclusion: This is the first study where the cytokine pattern has been analysed after intra-articular steroid injection and almost all patients improved clinically. However, there was no reduction in synovial macrophages, but T-cells as well as ICAM-1 diminished.
No change in IL-1 was detected. TNFα producing cells were remarkably few with a trend to diminish, but individual patterns were seen. In this study, steroid treatment did effect the inflammation but it did not disappear completely microscopically as well as macroscopically. The therapeutic effects have mostly been shortlived and this study may provide an explanation for this. .Luc into the murine knee joint cavity of DBA/1 mice before onset of collageninduced arthritis (CIA). IL-18BPc overexpression significantly reduced local knee joint swelling in CIA with 66% (P < 0.001) and distal paw swelling with approx. 50% (P < 0.01) compared to the control vector. Furthermore, local IL-18BPc resulted in lower serum levels of IL-6 compared to the control (respectively 5.0 pg/ml and 12.7 pg/ml, P < 0.001). Serum titers of specific IgG1, IgG2a and total IgG antibodies directed towards collagen type II showed no significant differences between control and IL-18BPc treatment, indicating that the effect seen on arthritis by overexpression of IL-18BPc in the joint was not caused by an IL-18BPc effect on humoral immunity. These results clearly show that IL-18 present in the arthritic joint plays an important proinflammatory role and demonstrate that adenoviral overexpression of IL-18BPc in the synovium is an efficacious local treatment in experimental arthritis.
The bias for Th1 cell differentiation of rheumatoid arthritis T cells is characteristic of memory but not of naive T cells A Skapenko, J Wendler, PE Lipsky, JR Kalden, H Schulze-Koops
Nikolaus Fiebiger Center for Molecular Medicine, Clinical Research Group III, and Department of Internal Medicine III, University Erlangen, Germany and NIAMS, Bethesda, USA
An impaired ability of CD4 memory T cells to differentiate into immunomodulatory Th2 cells has been documented in patients with rheumatoid arthritis (RA) and has been implicated in the initiation and perpetuation of the characteristic Th1 dominated rheumatoid inflammation. To determine the stage of T-cell maturation at which the bias for Th1 cell differentiation becomes manifest, we investigated Th cell differentiation from resting CD4 CD45RA (naive) and CD45RO (memory) T cells in patients with untreated early RA (mean disease duration <8 months) and in age-and sexmatched healthy controls in vitro. No differences in the cytokine secretion profile, as assessed by flow cytometry, between patients and control subjects were detected in freshly isolated naive or in freshly isolated memory T cells. To test whether CD28 mediated Th2 differentiation from memory T cells was an effect of a particular anti-CD28 mAb, Th2 differentiation was assessed after priming of purified CD4 memory T cells with transfected myeloma cells expressing human CD80 and/or CD86. Whereas the mock control did not induce Th2 differentiation, priming in the presence of myeloma cells expressing CD80, CD86 or CD80 and CD86 significantly increased Th2 frequencies. Thus, Th2 differentiation from memory T cells can be induced by engaging CD28 with its natural ligands, CD80 and/or CD86. We next evaluated the possibility that activated T cells might prime bystander T cells for Th2 differentiation. CD4 memory T cells were activated with mAbs to CD3 and CD28 for five days. Flow cytometric analysis revealed that in contrast to resting T cells, activated T cells expressed CD80, however, at a low level. CD80 expressing T cells were fixed and cocultured with freshly isolated, syngeneic, CD4 memory T cells for five days in the presence or absence of exogenous IL-4, but without additional stimulatory signals. For control, priming was performed with fixed syngeneic T cells that were freshly isolated and, thus, negative for CD80. Priming with fixed, non-activated syngeneic T cells did not induce Th2 differentiation, even in the presence of exogenous IL-4. In marked contrast, priming with fixed activated T cells induced significant Th2 differentiation. This effect was dependent on exogenous IL-4, suggesting that the low levels of CD80 expressed on activated T cells were not sufficient to induce IL-4 transcription. However, the data indicate, that Th2 differentiation might be induced from bystander T cells by recently activated T cells through cognate T-T-cell interaction involving CD28. TCR independent generation of Th2 effectors might provide a way to control Th1 dominated cellular inflammation.
Autoantigens and autoantibodies
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Comparison of different immunoassays detecting anti-chromatin autoantibodies in systemic lupus erythematosus (SLE) P Roux-Lombard, S Mormile, JM Dayer
Division of Immunology and Allergy, Geneva, Switzerland
Introduction: Anti-double-strand DNA (dsDNA) autoantibodies are considered a hallmark of SLE and many assays have been devel-oped to improve the determination of these antibodies. Recently, autoantibodies to nucleosome, the fundamental unit of chromatin, have been shown to constitute a new and very specific marker of SLE. Methods: To evaluate the diagnostic value of (A) Crithidia lucillae indirect immunofluorescence (CLIFT), anti-dsDNA immunoassays using (B) purified dsDNA (Quanta LiteTM dsDNA ELISA INOVA, San Diego, CA), (C) recombinant plasmid dsDNA (EliATM, Pharmacia, Freiburg, Germany) and (D) anti-nucleosome immunoassay (Quanta Lite Chromatin ELISATM, INOVA, San Diego, CA), we investigated in a prospective study all the sera sent to our laboratory for anti-dsDNA detection during 2 months. 122 sera were enrolled in this study of which 16 appear to be from SLE patients and we assessed the sensitivity and specificity of the assays. We also compared a group of 30 SLE patients with other autoimmune diseases (19 cutaneous lupus, 22 Sjögren's syndrome, 14 systemic scleroderma) in a retrospective study.
Results: In the prospective study, the sensitivity for SLE was 13%, 53%, 47% and 60% for test A, B, C and D, respectively; the specificity was 99%, 94%, 94% and 99% for test A, B, C and, respectively. Results were similar in the retrospective study. Conclusion: Anti-nucleosome autoantibodies are sensitive and specific markers for SLE. However, other studies are necessary to evaluate if they are also useful in monitoring disease activity. Objective: We discuss the presence of anti-keratin antibodies (AKA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies of the IgG class in sera of patients with defined juvenile idiopathic arthritis (JIA) of various subgroups with more than one year duration of the disease. Methods: An indirect immunofluorescence test on rat oesophagus substrate (ImmuGloTM, Immco Diagnostics, Buffalo, USA) and enzyme-linked immunosorbent assay (Immunoscan RA, Eurodiagnostica, The Netherlands) were used for the detection and quantification of AKA and anti-CCP antibodies in 140 patients with JIA (64 male and 76 female) aged 2-47 years (median 16.5 years). Results: Overall, AKA were found in 40/140 patients (28.6%, P = 0.04) including 2/11 systemic arthritis (18.2%), 2/32 oligoarthritis (6.3%), 18/52 RF negative polyarthritis (34.6%, P = 0.01), 14/18 RF positive polyarthritis (77.8%, P = 0.000002), 2/15 enthesitis related arthritis (13.3%) and 2/3 psoriatic arthritis patients. AKA were not found in a very small cohort of patients with extended oligoarthritis (n=4) and unclassifiable arthritis (n=5). Only 7/122 (5.7%) patients were positive for anti-CCP. The correlation between AKA and anti-CCP was 77.1% (P = 0.05).
Conclusion:
We conclude that while AKA antibodies measured using IIF on rat oesophagus can be detected in patients with definite JIA with more than 1 year duration of the disease, only rare occurrence of anti-CCP was observed. We conclude that AKA occurred in any JIA patient category, however when statistically compared with healthy controls significantly higher frequencies were found only in a cohort of RF positive and RF negative polyarthritis. In this study we examine the characteristics of the autoantibody response to find evidence for the involvement of potential mechanisms including upregulated synthesis of natural autoantibodies, polyclonal IgM activation, the production of cross reactive rheumatoid factors, or a response to apoptotic release of nucleosomal material. Methods: IgM antibodies to IgG (rheumatoid factor), mitochondrial, microsomal, measles antigens and circulating nucleosome levels were measured prior to and following infliximab therapy. Sera containing induced anti-dsDNA antibodies were studied by immunofluorescent inhibition to examine cross reactivity.
Results:
• IgM antibodies to mitochondrial, microsomal and measles antigens were unchanged following infliximab therapy (pretreatment vs. post-8 weeks=ns).
• IgM anti-dsDNA were inhibited by dsDNA, but not by rabbit or human IgG, or histones.
• Levels of circulating nucleosomes fell following infliximab therapy (pre-treatment vs. post-2 weeks P ≤ 0.02; vs. post-4 weeks P ≤ 0.05).
Conclusion:
We were unable to find any evidence to support a role for upregulation of IgM natural autoantibodies, a polyclonal increase in IgM antibodies, cross reactive rheumatoid factors, or nucleosome release and consequent antigen drive. The induction of anti-dsDNA antibodies appears to be dependent on an, as yet, ill understood mechanism. To disclosure the nature of antigens involved in the triggering and the perpetuation of the disease we carried out the study of IgG, a monoclonal B-cell hybridoma, belonging to the VH3 family (DP 43), from rheumatoid synovial membrane, produced by electrofusion and without prior in vitro stimulation. The subject of the study was an RA patient with definite and active RA, featuring dense inflammatory infiltration with the occurrence of secondary lymphatic follicles in the affected joint. This hybridoma was analysed by PCR, immunohistology, immunoprecipitation and western blot, and the results were correlated with pathological data and parameters of local disease activity. By PCR we found out that this hybridoma had germline configuration IgVH genes with R/S ratio=1; it revealed specific binding (20 kDa) to nuclear extract of fibroblasts cell line (Hep2), later identified by mass spectrometry as the nuclear protein human histone (1B, 1C, 1D). Being this protein an exclusive nuclear protein involved in the chromatin condensation, it can be assumed that its implication in RA will be related to the perpetuation of the disease and inflammation after massive cell death, due to destruction of the joint tissues.
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Immunomic analysis of syovial fluid exosomes of rheumatic diseases patients A Sternjak*, S Bläß*, S Metzkow*, P Jungblut † , G Burmester*, SK Skriner* The composition of synovial exosomes has so far not been studied or compared to other diseases and normals. Autoimmune diseases like rheumatoid arthitis (RA) are characterized by autoantibodies to different proteins like BiP, hnRNPs and p205 which has not been charaterized in its nature. Different synovial exosomes from RA patients, reactive arthritis, and osteoarthritis patients and controls have been purified and anlysed for specific autoantigenic content by immunoblotting. P205 was found in all exosomal preperations in contrast to Bip and hnRNP A2, which could not be detected in the synovial exosomes fractions so far. Synovial Exosomal proteins haved been analysed by immunoblotting after 2D electrophoresis and immuneprecipitation. Based on that methods the specific autoantigenic protein content can be analysed now. After revealing the primary structure and molecular identity of the autoantigens, recombinant autoantigens will be produced and used for diagnostic as well as immunemodulatory purposes. In summary, the autoantigenic analysis of synovial exosomes revealed that p205 is associated with exosomal particles. The investigation of the synovial exosome protein content as well as the analysis of B and Tcell sitmulation potential, may thereby possibly lead to novel diagnostic and therapeutic strategies in rheumatic diseases. In rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other autoimmune rheumatic diseases, our understanding of the specificity of the autoantibody response and the role of autoantibodies in pathogenesis are limited. We developed antigen microarray technology to perform multiplex characterization of autoantibody responses. Antigen microarrays are produced by attaching thousands of proteins and peptides to addressable locations on the surface of solid supports using a robotic arrayer. Arrays are probed with serum from disease and control patients, followed by anti-human secondary antibodies covalently-conjugated to spectrally-resolvable fluorochromes. We initially developed a 'connective tissue disease' array containing structurally diverse autoantigens including nucleic acids, histones, hnRNPs, snRNPs, collagens, Ro, La, SCL-70, CENP-B, Jo-1, pyruvate dehydrogenase, and post-translationally-modified antigens. Array analysis of serum derived from patients with SLE, rheumatoid arthritis, Sjögren's syndrome, mixed connective tissue diseases, scleroderma, myositidies, and primary biliary cirrhosis identified autoantibody response patterns characteristic of these diseases (Fig. 1) .
We are now developing 'synovial proteome' arrays to study the autoantibody responses in RA, and have produced first-generation arrays containing 450 distinct protein and peptide candidate antigens derived from synovial joints. These include native and cit-rulline-modified filaggrin peptides, native and deiminated fibrinogen and vimentin, glucose-6-phosphate isomerase, collagen types I, II, III, IV and V, hnRNP-A2/RA33, hnRNP-D, immunoglobulins, HCgp39, BiP, and HSPs 60, 65, 70, and 90. We probe our arrays with sera and synovial fluid from RA and control patients. We are using our arrays to examine serial serum samples from patients with early RA to: (1) identify antigens targeted early in disease, and (2) examine for evidence of B-cell epitope spreading. 'Synovial proteome' arrays represent a powerful tool to study the breadth and specificity of autoreactive B-cell responses, and to identify candidate and define relevant autoantigens in RA. Antiphospholipid antibodies (aPL) are strongly associated with arterial and/or venous thrombosis and recurrent foetal loss. The only neurological manifestation satisfying the diagnostic criteria for the antiphospholipid syndrome (APS) is ischemic cerebrovascular insult (CVI). Because of previous contradicting reports on the association between aPL and CVI, we examined the occurrence of different aPL in a group of patients with CVI without an evident systemic autoimmune disease. 39 patients (26 women, 13 men, all under 40 years) were included in study. Blood withdrawal was performed twice after CVI at least 8 weeks apart. Sera were tested by enzyme linked immunosorbent assays (ELISA) for the presence of IgG, IgM and IgA anti-cardiolipin (aCL), anti-β2-glycoprotein I (aβ2GPI), anti-prothrombin (aPT) and anti-annexin V (aANXV) antibodies. Increased levels of IgG aCL were found in 3 (8%) patients and for IgA aβ2GPI in 1 (3%). In all aCL and aβ2GPI positive CVI patients only low positive levels of antibodies were detected. aPT were completely absent while aANXV were detected in 4 (10%) patients (3 had IgG and one IgM). aPL directed against serum antigens did not appear with a significant frequency in the studied group of CVI patients. But aANXV, directed against a tissue protein, might be important as one of the possible markers in at least some patients with CVI. Introduction: Anti-neutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3) are strongly associated with Wegener's granulomatosis (WG) and are thought to be involved in its pathogenesis. In vitro functional effects of these antibodies have been suggested to correspond better to disease activity than levels of PR3-ANCA. Methods: To investigate the relation between functional effects of PR3-ANCA and disease activity, we tested IgG from sera of 43 WG patients and four controls for their capacity to interfere with the proteolytic activity of PR3. Blood was drawn either during active disease or during remission of WG. The enzymatic activity of PR3 was determined using MeSuc-AAPV-pNA, casein, and by complexation of PR3 with α-1-antitrypsin (α-1-AT).
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Results: Most of the IgG samples from WG patients inhibited the enzymatic activity of PR3 and the complexation of PR3 with α-1-AT. A difference in the capacity to interfere with proteolysis of casein and with complexation of PR3 with α-1-AT was observed between samples taken during active disease and during remission of WG, but this was not observed for the hydrolysis of MeSuc-AAPV-pNA. However, PR3-ANCA titers giving fifty percent inhibition of the PR3/α-1-AT complexation and the proteolytic activity of PR3 for the hydrolysis of MeSuc-AAPV-pNA were lower for remission samples compared to samples during active disease, indicating a relatively higher inhibitory activity in the former samples. PR3-ANCA titers correlated with the inhibitory activity both for patients with active disease and for patients during remission.
Conclusion:
With a fixed amount of IgG, PR3-ANCA-containing IgG from patients with active disease had a higher inhibitory capacity towards the proteolytic activity of PR3 than did PR3-ANCA-containing IgG from patients during remission of WG. However, when correcting the results for the PR3-ANCA titer, PR3-ANCA of patients during remission had a relatively higher inhibitory capacity towards the proteolytic activity of PR3 than did PR3-ANCA of patients during an active phase. These results may indicate that PR3-ANCA of patients with active disease recognize different epitopes on PR3 than do PR3-ANCA of patients during remission of WG. These findings may have relevance for the pathogenicity of the antibodies. Background: The frequency of anti-Ro/SSA in SSc varies from 3% to 11% with immunoprecipitation assays and from 12% to 37% with ELISA. Significant associations were reported between anti-Ro/SSA and Sjögren's syndrome, pulmonary involvement and myositis in patients with SSc. Objective: To evaluate the frequency the association of antiRo/SSA antibodies and their fine specificity with clinical and immunological features in SSc.
Patients and methods:
We studied 193 patients with SSc (58 diffuse, 129 limited and 6 overlap syndromes) attending our outpatient clinic. Antibodies to ENA were determined by counterimmunoelectrophoresis (CIE) using rabbit thymus (Peel-Freeze) and human spleen extract as substrates. ELISA assay with recombinant 52 and 60 kD Ro proteins (Pharmacia) was performed on 107 sera, cut-off values were determined testing 75 sera from routine: 50 ANA negative and 25 ANA positive-ENA negative.
Results: Anti-Ro was detected by CIE in 12/193 patients (6%) and by ELISA in 14/107 (13%). As a whole, CIE and/or ELISA detected the presence of anti-Ro in 20 patients (Ro+). It was significantly associated with photosensitivity (P = 0.02), xerophtalmia (P = 0.05), raised ESR (P = 0.02), hyperγglobulinemia (P = 0.002), anti-La (P = 0.004) and antinucleolar antibodies (P = 0.02). AntiScl70 antibodies tended to be specifically associated with antiRo60 as compared with anti-Ro52 antibodies (P = 0.06). Anti-Ro+ patients had higher incidence of interstitial lung disease and slight reduction of DLCO at the moment of first evaluation, as compared with patients Ro-(P = 0.06), particularly with the subset anticentromere positive (P = 0.001). However, decrease of DLCO during follow-up was more frequent in patients Ro-(P < 0.001). This observation might be partially related to a longer steroid treatment received by patients Ro+ (P < 0.03).
Conclusion:
Antibodies to Ro/SSA are not infrequently detected in SSc. They are associated with a subset of disease characterized by clinical and serological features commonly associated with antiRo/SSA independently from the underlying disease. Anti-Ro+ SSc patients tended to have an earlier lung involvement apparently less evolving as compared to anti-Ro-patients.
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Autoantibodies to the TNF-α α translational regulators TIA-1 and TIAR occur frequently in sera of patients with SLE and scleroderma Anti-endothelial cell antibodies (AECA) have been reported in such a vast array of conditions associated with vasculitis that the related autoantigens have become extremely difficult to identify. We have, therefore, used a molecular cloning approach to define endothelial cell (EC) target structures by screening a human umbilical vein EC (HUVEC) cDNA expression library. Total RNA was extracted from HUVECs and purified by oligo-dT cellulose chromatography. A commercial kit was used to synthesize cDNA which was inserted into the EcoRI/XhoI-digested and dephosphorylated lambda ZAP Express vector. The construct was incorporated into phages and transformed with E. coli strain XL1 Blue. After the addition of AECAs, positive clones were isolated in suspending medium, purified and incorporated again into the XL1. The insert-containing phagemids were exised from recombinant phages and introduced into E. coli XLOLR strain. The restriction fragments, obtained from the cDNA inserts by EcoRI endonuclease digestion, were sequenced by the dideoxy-chain termination method with two primers, T3 (AATTAACCCTCACTAAAGGG) and T7 (CGGGATATCACTCAGCATAATG). The sequences were examined for analogy in the GenBank and EBML nucleic acid data banks. Two sera, one from a patient with systemic lupus erythematosus (SLE) and another from a patient with Wegener's granulomatosis (WG), both strongly AECA-positive in our in-house cell-ELISA, were used to screen the bank. The SLE serum recognized methyltransferase, NADH dehydrogenase and unidentified components, whereas the WG serum recognized methyltransferase, GAPDH and unidentified structures. AECAs could thus be associated with a bulk of autoantibodies targeting various enzymes, or get inside the ECs to bind to such proteins. Results: Fluorescence intensities and patterns on HEp2 and HEp2000 were strongly correlated (Spearman's Rho=0.838; P < 0.001 and 0.787; P < 0.001, respectively). 292 samples were negative on HEp2 and HEp2000, 18 of these had a positive LIA result. Reactivities seen are towards one or more RNP antigens (8 patients); Ro52 and Ro60 (1 patient); mono SSB (4 patients); Jo1 (1 patient); SmD (1 patient); RNPC, Ro52, Ro60, SSB, sclero70 (1 patient); RNPC and SSB (1 patient); SmB (1 patient). Two out of 26 patients, positive on HEp2 but negative on HEp2000, showed reactivities: one with anti-Jo1 and one with anti-RNPC. Three out of 23 patients, positive on HEp2000 but negative on HEp2, showed reactivities: one with Ro52, one with SSB and one with Ro52, Ro60 and SSB (SSA-fluorescence pattern on HEp2000). A significant fraction of patients with positive LIA results who were negative on IIF had classical systemic disease. Detailed diagnostic and serological validation will be discussed. The SSA pattern was seen in 9% of the HEp2000 positive samples, all of them showed Ro52 or Ro60 positivity on LIA. When considering the total population, 79/495 were positive on LIA, of whom 73.4% were detected with HEp2 and 74.4% were detected with HEp2000. Conclusion: IIF has no optimal sensitivity for detecting anti-ENA reactivities. In the context of clinical suspicion, anti-ENA testing is warranted, regardless of the IIF result. Background: The highly specific presence in serum of autoantibodies directed against intracellular neutrophil proteins such as PR3 (PR3-ANCA) suggests a pathophysiological role of these autoantibodies in patients with necrotizing small vessel vasculitis. A stable but interindividually highly variable membrane expression of PR3 has been found on resting neutrophils. We hypothesized that, in patients with PR3-ANCA related vasculitis, a higher expression of PR3 on neutrophil membrane would lead to more interaction with PR3-ANCA and could thereby influence the extent or course of the disease. Methods: PR3 expression on unstimulated isolated neutrophils from patients with PR3-ANCA related vasculitis was determined by FACS analysis using anti-PR3 murine mAb 12.8. Patients were divided according to the distribution of neutrophil membrane PR3 in 3 groups: low, bimodal, and high. Disease extent at diagnosis was scored with the Birmingham Vasculitis Activity Score (BVAS). Actuarial relapse-free survival was calculated from diagnosis to the first relapse and compared between groups with the logrank test. Results: 89 patients (age 49±16.6; 47 male/42 female) with PR3-ANCA related vasculitis followed at our department were included. At diagnosis, renal involvement was present in 52 (58%) and pulmonary involvement in 49 (55%) patients, BVAS was 23±10.5. During follow-up (81±67 months) 50 patients had one or more relapse. Age at diagnosis, organ involvement and BVAS at diagnosis were not different between patients with low (n=32), bimodal (n=26), and high (n=31) neutrophil membrane PR3 expression. However, median relapse-free survival was 104.5 months in patients with low PR3 expression as compared to 36.6 and 30.8 months in patients with bimodal and high PR3 expression, respectively (P = 0.023). Clinical manifestations at first relapse of vasculitis were not different between these groups. Conclusion: The level of individual PR3 expression on resting neutrophils is significantly associated with risk for relapse in patients with PR3-ANCA associated vasculitis, but not with disease extent or manifestations at diagnosis or relapse. These data support the hypothesis that interaction in vivo of ANCA with PR3 expressed on neutrophil membrane plays a role in the pathophysiology of PR3-ANCA related vasculitis. Freshly isolated BAL CD8 + T cells from 26 individuals were tested for expression of cytokines, chemokines, growth factors, and receptor genes, using DNA microarrays. Hierarchical cluster analyses showed two groups of arrays. Group 1 included all 10 patients with lung inflammation and two patients without. Arrays from the other 7 patients without lung inflammation clustered with all 7 arrays from controls in group 2. Differences in gene expression indicated that CD8 + T cells in group 1, compared to group 2, were more likely to be activated, express type 2 cytokines, and stimulate extracellular matrix deposition, and less likely to undergo activationinduced cell death. T-cell activation was suggested by increased expression of LIGHT, neurotropin-4, CD100, CD6, integrin b1 and decreased expression of VIP R1 genes. Type 2 cytokine production was suggested by increased expression of CCR4, G-CSF R and IL-13 Ra and decreased expression of TRANCE and TNF R1 genes. Reduced expression of TNF R1, TNF R11, TRAIL R1, CD30 L and Fas genes suggested that CD8+ T cells from Group 1 were less likely to die following activation. Increased gene expression of oncostatin M, which simulates fibroblast proliferation and collagen production, integrin b6, which can activate TGF-β, FGF17, FGF4, and membrane type-1 and -2 matrix metalloproteinases was seen. To confirm some of these results, increased IL-4 mRNA had been reported in our previous work, and increases in oncostatin M and activated TGF-β proteins in BAL fluids from patients with lung inflammation were confirmed by ELISA. These findings suggest that activated CD8 + T cells are part of a pathway that leads to lung fibrosis in scleroderma. In rheumatoid arthritis (RA), besides CD4 + T cells also monocytes play an important role in the disease process. Therefore we investigated whether the suppressive CD4 + CD25 + T cells could affect monocyte activation as well as T-cell activation. CD4 + T cells and monocytes were isolated from peripheral blood mononuclear cells from healthy donors via MACS isolation techniques. CD4 + T cells were separated into CD4 + CD25 + and CD4 + CD25 -T cells. T cells and monocytes were cocultured for two days without or with anti-CD3 mAb, after which proliferation, cytokine production and phenotypic markers were investigated. Coculture of monocytes with CD4 + CD25 -T cells in the presence of anti-CD3 mAb resulted in strong T-cell proliferation, production of cytokines (TNF-α, IFN-γ, IL-1β, IL-10), upregulated expression of HLA II, CD40 and CD80 and remaining high CD86 levels on the monocyte/macrophage. In contrast, coculture of monocytes with CD4 + CD25 + T cells and anti-CD3 mAb resulted in T-cell anergy, low levels of cytokine production, reduced upregulation of HLA II, CD40 and CD80 and downregulation of CD86. We are currently investigating how this altered activation affects the antigen-presenting and/or cartilage-destructive capacity of the monocytes/ macrophages.
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In conclusion, we demonstrate that anergic/-suppressive CD4 + CD25 + T cells can suppress -besides T-cell responses -also the activation of monocytes. Further investigation into the function of these suppressive CD4 + CD25 + T cells in RA patients as well as understanding their regulatory mechanism might elucidate their potential role in the pathogenesis of RA. 
CLB, Amsterdam, The Netherlands
The mechanisms that lead to the formation of autoantibodies are not understood. Accumulating data suggest that autoantigens might be characterized by post-translational modifications that are part of the natural apoptosis process such as granzyme B cleavage (i.e. topoisomerase I, LA (SS-B), U1-70 kd), caspase cleavage (i.e. topoisomerase I and II), phosphorylation/dephosphorylation (i.e. ribosomal P proteins, LA (SS-B), transglutaminase crosslinking (i.e. histone H2B) and deimination (arginine-citrullin change in fibrin or fibrinogen). T cells, which have been negatively selected or tolerized against native autoantigens, might be primed by modified autoantigens and deliver help to self-reactive B cells. So far, there have been only few reports about autoantigen specific T cells.
Since the frequencies of those T cells in the peripheral blood are very low, autoantigen specific T-cell responses are difficult to detect. In our study we are combining the use of monocyte derived dendritic cells (DC) as professional antigen presenting cells with intracellular cytokine staining for the detection of T-cell responses. Monocytes and lymphocytes are purified from freshly isolated PBMC by density gradient centrifugation. Lymphocytes are frozen in liquid nitrogen until usage. Monocytes are differentiated into immature dendritic cells in culture medium containing either 1% FCS or 10% autologous serum and GM-CSF and IL-4. Maturation is induced by addition of GM-CSF, LPS, TNF-α and IL-1-β in the presence or absence of a specific antigen. Mature DC expressing antigen derived peptides are washed and cocultured with thawed autologous lymphocytes. After 4 hours, brefeldin A is added and lymphocytes are intracellulary stained with CD3, CD4, CD69 and TNF-α mAb after o/n culture. We will use this system to identify possible T-cell specific autoantigens by using granzyme B cleaved nuclear extracts and purified modified nuclear antigens.
Tolerance induction in mice by antibodies to T-cell epitopes R Laub, R Brecht, F Emmrich
Institute of Clinical Immunology, Leipzig, Germany
CD4/DR3 mice lack murine cd4 but express human CD4 specifically on helper T cells, and HLA-DR3 as its natural counter ligand (CD4/DR3 mice). The injection of these mice with anti-human CD4 prior to immunization with tetanus toxoid (TT, day 0) totally blocked the formation of specific Abs. When these mice were left untreated for at least 30 days, and were then re-exposed with TT, but in the absence of anti-human CD4, they consistently failed to induce specific antibodies (long-term unresponsiveness). Importantly, the concurrent injection of TT and anti-human CD4 at day 0, followed by another two anti-CD4 treatments also led to tolerant animals indicating that tolerance was inducible as late as the antigen exposure is provided. We demonstrate a limited ability of spleen cells to respond to TT in vitro indicating that T cells are essentially involved in the maintenance of tolerance. Objective: Psoriasis and psoriatic arthritis (PsA) are thought of as T-cell mediated diseases. LFA-3/CD2 interaction plays a significant role in T-cell activation. Alefacept, an LFA3-IgG1 fusion protein, blocks LFA3-CD2 interactions resulting in inhibition of Tcell responses and T-cell apoptosis which could be beneficial in patients with active PsA. Methods: Eleven patients with active PsA were treated with alefacept for 12 weeks in an open label design. Clinical joint assessment, Psoriasis Area and Severity Index (PASI), and peripheral blood (PB) assessments were performed at baseline, after 4, 9, 12, and 16 weeks of treatment. Serial synovial tissue (ST) biopsies of an index joint (knee, ankle, wrist or MCP joint) were obtained by arthroscopy at baseline, 4 and 12 weeks. Results: At completion of treatment 6 out of 11 (56%) treated patients fulfilled the DAS response criteria, 9 patients (82%) fulfilled the DAS response criteria at any point within the study. Seven of 11 (64%) treated patients showed improvement (mean 50%) of their skin psoriasis. In the ST there was a statistically significant reduction in CD4+ lymphocytes (P < 0.05), CD8+ lymphocytes (P = 0.05), and CD68+ macrophages (P < 0.02) in the synovial samples after 12 weeks of treatment compared to baseline. Patients fulfilling the DAS response criteria demonstrated a higher baseline ration and significant reduction in CD4+CD45RO+ cells in both ST and PB where non-responders demonstrated only reductions in PB.
Conclusion:
The improvement in clinical joint score, skin psoriasis, and changes in synovial tissue after treatment with alefacept supports the hypothesis that T-cell activation plays an important role in this chronic inflammatory disease. Furthermore, since alefacept, a specific T-cell agent, led to decreased macrophage activation, the data indicate that T cells orchestrate synovial inflammation in psoriatic arthritis. 
University of Leipzig, Leipzig, Germany
Fibroblasts are considered to be a crucial cell population for disease progression, as well as joint destruction in rheumatoid arthritis. Recent data underline the potency of rheumatoid synovial fibroblast-like cells to induce the destruction of cartilage and bone, e.g. following intra-articular injection into SCID mice. We have isolated a fibroblastoid cell line by co-cultivation of human rheumatoid fibroblasts with murine fibroblasts. The generated cell line exhibits characteristics of rheumatoid fibroblasts and genetic alterations indicating a transformed phenotype. These cells have been shown to induce a rapid destruction of articular cartilage following intraarticular instillation. Fibroblastoid cells (LS48) were examined for cytogenetic characteristics, morphology, surface molecules, cytokine secretion, and functional parameters. 500,000 cells were injected directly into SCID mouse knee joints to induce cartilage destruction. Mice were monitored for joint swelling, serological parameters and by radiological methods. Furthermore, the effects of immunosuppressive drugs such as cyclosporine A, methotrexate, and FK 506 were investigated in this model. In addition, transfection of LS48 was performed with IL-11 as well as IL-15 prior to arthritis induction to investigate influence on cartilage destruction. Finally, the histology of cartilage destruction was explored. LS48 shows characteristics of a fibroblast-like cell but is of murine origin. Secretion of matrix metalloproteinases 3, 9 and 13 as well of interleukine-6 and tumor necrosis factor revealed similarities to human invasive rheumatoid synovial membrane fibroblasts. Rapid progressive cartilage destruction within 10 days was induced by instillation into SCID mouse knee joints. Morphology revealed invasion of fibroblast-like cells into the articular cartilage. Destruction could be reduced by methotrexate but not by cyclosporine A or FK 506, indicating a fibroblast-directed action of methotrexate connected to reduction of joint destruction in RA patients. Transfection with cytokines did not act on cartilage destruction, but IL-11 reduced apoptosis of chondrocytes. Induction of cartilage destruction by intra-articular application of murine fibroblast-like cells, in particular LS48, is a rapid and highly reproducible model for investigating invasive arthritis and can be modulated by drugs or gene transfer. This provides the opportunity to check novel therapeutic strategies for the treatment of arthritis, especially focussing on the reduction of cartilage erosion. 
